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Toxoplasma gondii is an obligate intracellular pathogen that is a cause of significant morbidity and mortality in
humans and animals. The immune response necessary to control this infection requires successful
coordination of strong innate and adaptive responses. Recognition of the pathogen by innate accessory cells
such as macrophages, neutrophils, and dendritic cells induces the release of IL-12 that activates NK and T
cells to produce protective IFN-g, the major mediator of immunity to T. gondii. T. gondii has many
mechanisms to limit the activation of innate cells and to reduce the production of IL-12. One of the ways T.
gondii achieves this is by inducing the phosphorylation of the transcription factor Signal Transducer of
Activation 3 (STAT3) that leads to repressed pro-inflammatory responses such as diminished IL-12
production. How STAT3 antagonizes inflammatory responses is poorly understood but the Suppressors of
Cytokine Signaling (SOCS) proteins are downstream candidate molecules that antagonize cytokine signaling.
Recent studies have identified SOCS proteins as being important during infection with a number of
pathogens and have provided insights into how intracellular pathogens affect STAT signaling to promote their
replication and survival. In particular, SOCS1 is thought to inhibit IFN-g signals whereas SOCS3 antagonizes
IL-6 signals. Studies have shown that both of these proteins are upregulated in other models but little is
known about how they contribute to the outcome of infection. This thesis provides evidence that the IL-6
signaling in macrophages reduces the cell’s ability to produce IL-12 that is enhanced in the absence of SOCS3.
Furthermore, infection of SOCS3 conditional knockouts leads to acute susceptibility with high parasite
burdens associated with impaired IL-12 production. Blocking anti-bodies to IL-6 as well as addition of
exogenous IL-12 rescues the lethality in these mice suggesting that IL-6 is a natural antagonist of IL-12
production during infection with T. gondii. This thesis will discuss the roles that IL-6, STAT3, and SOCS3
play during infection with T. gondii and how these molecules affect cytokine regulation, cellular recruitment,
and microbicidal activity and also how these studies enhance our understanding of inflammation and
resistance to infection.
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Abstract 
 
Innate signals in the macrophage determine the severity of Toxoplasma 
gondii infection 
 
Ryan J. Whitmarsh 
 
Christopher A. Hunter 
 
 
Toxoplasma gondii is an obligate intracellular pathogen that is a cause of significant 
morbidity and mortality in humans and animals.  The immune response necessary to 
control this infection requires successful coordination of strong innate and adaptive 
responses.  Recognition of the pathogen by innate accessory cells such as macrophages, 
neutrophils, and dendritic cells induces the release of IL-12 that activates NK and T cells 
to produce protective IFN-γ, the major mediator of immunity to T. gondii.  T. gondii has 
many mechanisms to limit the activation of innate cells and to reduce the production of 
IL-12.  One of the ways T. gondii achieves this is by inducing the phosphorylation of the 
transcription factor Signal Transducer of Activation 3 (STAT3) that leads to repressed 
pro-inflammatory responses such as diminished IL-12 production.  How STAT3 
antagonizes inflammatory responses is poorly understood but the Suppressors of 
Cytokine Signaling (SOCS) proteins are downstream candidate molecules that antagonize 
cytokine signaling.  Recent studies have identified SOCS proteins as being important 
during infection with a number of pathogens and have provided insights into how 
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intracellular pathogens affect STAT signaling to promote their replication and survival.  
In particular, SOCS1 is thought to inhibit IFN-γ signals whereas SOCS3 antagonizes IL-6 
signals.  Studies have shown that both of these proteins are upregulated in other models 
but little is known about how they contribute to the outcome of infection.  This thesis 
provides evidence that the IL-6 signaling in macrophages reduces the cell’s ability to 
produce IL-12 that is enhanced in the absence of SOCS3.  Furthermore, infection of 
SOCS3 conditional knockouts leads to acute susceptibility with high parasite burdens 
associated with impaired IL-12 production.  Blocking anti-bodies to IL-6 as well as 
addition of exogenous IL-12 rescues the lethality in these mice suggesting that IL-6 is a 
natural antagonist of IL-12 production during infection with T. gondii.  This thesis will 
discuss the roles that IL-6, STAT3, and SOCS3 play during infection with T. gondii and 
how these molecules affect cytokine regulation, cellular recruitment, and microbicidal 
activity and also how these studies enhance our understanding of inflammation and 
resistance to infection. 
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Introduction 
 
 
Toxoplasma gondii is an opportunistic pathogen of patients with a variety of 
primary and secondary deficiencies in T cell function and also is an important cause of 
disease in livestock 1-3.  This parasite was first identified in the early part of the 20th 
century as a parasite of rodents, but was subsequently linked to human disease as an 
opportunistic infection of immune-compromised patients, developing fetuses, and 
patients with Acquired Immunodeficiency Syndrome (AIDS) whose T cell numbers have 
fallen to critically low levels to allow reactivation of the parasite 4-7.  Other immune-
compromised individuals that have T cell defects are also susceptible to primary and 
reactivated toxoplasmosis and these patients illustrate the critical role for T cell-mediated 
immune responses in controlling this infection 8-11. 
Given its ability to be easily sustained in tissue culture, infect mice, and be 
genetically engineered, T. gondii has become a useful laboratory tool for researching the 
molecular genetics of parasites, immunology, and host-pathogen interactions. In addition, 
T. gondii provides a robust model of an intracellular pathogen that requires strong Th1-
mediated immunity for control. Thus, basic studies using T. gondii have helped define the 
importance of cytokines such as IL-12 and IFN-γ in the killing and clearance of 
intracellular pathogens by mechanisms including but not limited to oxygen radicals, 
GTPase colocalization, autophagy, and proteasomal degradation 12-21.  Analysis of 
immunity to T. gondii has also increased our understanding of the role of cytokines such 
as IL-6, IL-10, TGF-β, and IL-27 in limiting inflammation 22-27.  IL-6 has many functions 
in Th17, Treg, and neutrophil biology and historically has been associated with pro-
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inflammatory responses and is required for chronic resistance to T. gondii.  As a result of 
this work, IL-6 has emerged as an important regulatory cytokine that can inhibit acute 
inflammatory responses from macrophages and will be the subject of much of Chapters II 
and III of this thesis. 
This thesis will address the role of macrophage-mediated killing and clearance of 
T. gondii and the signals that regulate this process.  Chapter I will provide a broad 
overview of the biology of T. gondii and the immune mechanisms needed to control this 
pathogen.  Chapter II will focus on the signaling events that follow infection of a cell by 
T. gondii and how these signals regulate survival of the parasite.  Specifically, Chapter II 
will describe how T. gondii induces Signal Transducer and Activator of Transcription 3 
(STAT3) and will highlight how this activation limits IL-12 production.  Chapter III will 
introduce the relevance of IL-6 to parasite control and provide evidence that IL-6 is a 
prominent inhibitor of IL-12 responses in the absence of its negative regulator, 
Suppressor of Cytokine Signaling 3 (SOCS3). This section will also address how IL-6 
inhibits acute immune responses and will discuss what effects the cytokine has on Th1 
immunity and intracellular killing of T. gondii.  Chapter IV will discuss other studies 
involving the motility of T. gondii and biological aspects of the parasite that help dictate 
surival and dissemination. Finally, Chapter V will conclude this thesis with a discussion 
of research that has arisen from this work and address future directions suggested by this 
work. 
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Toxoplasma gondii 
Biology 
T. gondii has been studied for over 100 years and much of its biology and life-
cycle are well described.  T. gondii exists in several forms in its definitive host, the cat, as 
well as its intermediate hosts.  Cat populations are vital to transmission, however, as T. 
gondii infection does not occur on isolated islands without feline populations 28.  The 
transmission cycle of T. gondii is described in detail in Figure 1. There is a motile, 
proliferative form called the tachyzoite which allows for dissemination within the host 
and there is a cystozoite form called the bradyzoite, which is located within muscle and 
brain tissues and allows persistence and horizontal transmission following ingestion 28-31.  
This latter process can occur through the consumption of contaminated meat or the 
ingestion of oocysts from the environment 32. Oocysts are shed in the feces of wild and 
domestic felids, the definitive host, and ingested by other small animals such as birds and 
rodents. Once consumed, the intestinal digestive enzymes induce activation of the 
sporozoite/bradyzoite into a tachyzoite that invades a cell and reproduces asexually by a 
process known as endodyogeny, subsequently disseminating through the body.33, 34.  
 5 
 
 
Figure 1. Life cycle of T. gondii. A. Cats are the definitive host and become infected 
following consumption of infected prey animals, typically rodents and birds.  B. Sexual 
reproduction occurs with the feline intestine and oocysts are shed fecally.  C. 
Intermediate hosts, i.e. warm-blooded non-feline animals, ingest oocysts from soil and 
water containing excreted cysts.  These cysts become activated in the stomach of hosts, 
disseminate, infect new cells, and encyst in tissues like muscle and brain. D. Humans are 
infected similarly by oocysts ingested from infected water, fecal-oral transmission from 
contact with infected areas such as litterboxes, and undercooked meat.  E. Vertical 
transmission of T. gondii is possible from recently infected mothers leading to congenital 
toxoplasmosis.  F. An intact immune response in the host drives development of 
tachyzoites into bradyzoites or the cyst form. 
Adapted from the CDC, http://www.dpd.cdc.gov/dpdx/html/Toxoplasmosis.htm 
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Epidemiology and Clinical Significance 
T. gondii was first identified in 1907 when Nicolle and colleagues identified a 
crescent-shaped parasite in rodent tissues at the Institut Pasteur in Tunis 35.  Based on its 
morphology, they named the parasite Toxoplasma gondii from the Latin toxo meaning arc 
or bow and plasma meaning life 35.  Gondii was a misspelled version of the rodent host 
from which it was isolated, Ctenodactylus gundii 35.  Although originally described as a 
parasite of rodents and later a rabbit in Brazil 36, it was identified nearly 30 years later in 
the brain of a 3 day-old newborn with encephalomyelitis 37.   Following additional 
confirmation of T. gondii isolates in tissues from humans presenting with various 
conditions, a causal link between infection and some forms of encephalitis, 
choriomeningitis, and retinitis began to emerge 37-39.  T. gondii infects multiple 
mammalian hosts and current estimates of seroprevalence range from 20-30% of humans 
worldwide 39.  As a result, T. gondii is now considered a pathogen of both clinical and 
veterinary significance given its wide prevalence and the ability to cause clinical disease 
in humans and animals. 
T. gondii is one of the most prevalent parasitic infections in the world, recognized 
as one of the leading causes of waterborne illness internationally, and accounts for 
approximately 20% of the deaths related to foodborne illnesses in the United States 40.  
Estimates vary, but T. gondii seroprevalence in the U.S. has been described to be between 
10 and 30% while achieving rates upwards of 40-70% in countries such as France, Brazil, 
and parts of Africa39, 41-45.  
Although T. gondii was first identified in humans associated with clinical disease, 
seroprevalence studies indicate that most chronic infections are asymptomatic in 
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immune-competent individuals.  However, these cases are likely underrepresented as 
symptoms such as fatigue, nausea, fever, and lymphadenopathy often go unreported.   
Conversely, there have been reports of susceptible populations of healthy individuals that 
develop disease, usually associated with unique strains 46. The more extreme cases may 
present with myocarditis, splenomegaly, hepatitis, pneumonia and severe 
lymphadenopathy 47-51.  These severe clinical manifestations are rare in immune-
competent individuals but more frequent in immuno-compromised hosts such as persons 
living with HIV/AIDS and fetuses 38. 
Congenital transmission usually occurs following primary infection during 
pregnancy although such infections do not necessarily lead to transmission 38, 39.  
Previous exposure to T. gondii induces natural immunity involving T cell responses and 
antibodies that make it less likely that vertical transmission will occur.  There is a 
correlation with the gestation time and disease severity and incidence; infections during 
the 1st trimester are less common and more severe while the opposite is true for infections 
occurring during the 2nd and 3rd trimesters 52.  Infection in utero may result in 
spontaneous abortions in humans39, 53, 54 or may manifest as fetal hydrocephaly, 
splenomegaly, hepatomegaly, impaired development, altered neurological function, and 
mental retardation 39, 53, 54. Although most infections are considered mild, some disease 
may manifest later during life, often during puberty 38. 
 
T. gondii and HIV 
Since the advent of the HIV pandemic, T. gondii has emerged as a significant 
cause of morbidity and mortality in human populations and remains one of the most 
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clinically important parasitic infections worldwide.  During the early 1980’s, there was a 
large increase in clinical toxoplasmosis or toxoplasmic encephalitis (TE) in patients 
presenting with a novel immunodeficiency disease that resulted in loss of T cell 
populations 55, 56.  It was soon discovered that along with Kaposi’s Sarcoma Herpes Virus 
(KSHV) and Pneumocystis carinii, T. gondii was an opportunistic pathogen in these 
HIV/AIDS patients 57.  It is now recognized that patients with primary or acquired 
immune-deficiencies such as HIV/AIDS, certain immune cell defects such as Hyper IgM 
Syndrome, immune-suppressive cancers or those undergoing suppressive chemotherapy 
treatments, and transplant recipients are at risk for primary or reactivation of a latent 
infection 7, 8, 10, 58, 59.  Overall, disease tends to be associated with strong defects in T cell 
function and therefore it is not surprising that patients with HIV/AIDS whose CD4+ T 
cell counts fall below 200 cells/mm3 have difficulty controlling the parasite 5. However, 
the development of highly active anti-retroviral therapy (HAART) has helped restore 
immune function in HIV/AIDS patients and decreased the incidence and severity of 
clinical TE 60, 61.  
 
Parasite Morphology and Motility 
 T. gondii belongs to the phylum Apicomplexa and is closely related to a number of 
similarly medically important parasites such as Cryptosporidium species and the malarial 
parasites of the Plasmodium genus 62. These pathogens are significant causes of 
morbidity worldwide and studies have identified much of the basic biology, transmission 
cycle, and pathogenicity yet few have addressed how structural proteins influence host-
pathogen interactions and virulence. 
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 Apicomplexans contain many unusual subcellular structures and organelles 
including the inner membrane complex (IMC), a series of flattened vesicles located 
beneath the plasma membrane (PM), which comprises the pellicle along with the PM 63, 
64.  Many proteins are associated with the pellicle and involved in parasite motility and 
invasion. TgPHIL1 (Photosensitized INA-Labeled protein 1) is a highly conserved 
protein among Apicomplexans but shares little homology in other phyla 63. Although 
TgPHIL1 is membrane associated, TgPHIL1 extracts much like a cytoskeletal protein 
suggesting that it has functions in motility and invasion. In vitro, TgPHIL1 knockout 
parasites show distinct morphological differences from wild type parasites and are 
outcompeted in viability assays (Barkhuff, in press).  During infection, deletion of 
TgPHIL1 does not enhance survival in the mice however, the parasites have a similar 
rounded morphology, disseminate less quickly, and infected mice have lower parasite 
burdens.  This suggests that TgPHIL1 is involved in some aspect of parasite replication, 
invasion, and dissemination. 
 Similarly to TgPHIL1, Apical membrane antigen-1 (AMA1) is a microneme 
protein that is highly conserved among Apicomplexan parasites and seems to be involved 
in parasite motility and invasion 64-66.  AMA1 has received considerable attention as a 
malaria vaccine candidate given its proposed roles in Plasmodium dissemination 67-69. 
Antibodies against AMA1 inhibit invasion 66, as do phage-displayed peptides derived 
directed against Plasmodium AMA1 70-72 A tetracyline-inducible deletion of a conditional 
AMA1 mutant shows that AMA1-depleted parasites are impaired in their ability to attach 
to host cells and to regulate rhoptry secretion, necessary for productive invasion and 
immunity evasion 63.   
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Parasite Virulence 
 There is evidence that strain differences in T. gondii impact clinical disease.  
Originally, T. gondii was described as consisting of three clonal lineages 73,  but, more 
recent studies have described T. gondii as being more genetically variable.  In North 
America and Europe, three common strains (I, II, and III) exist.  These are also present in 
other parts of the world such as South America and Africa, but are prevalent at a varying 
frequency alongside various recombinant and novel genotypes 73.  Associated with 
genetic variation are differences in parasite virulence.  Typically, type I strains, of which 
RH is the most widely used laboratory strain, are highly virulent with a lethal dose (ld100) 
of 1 sufficient to kill 100% of mice 74, 75.  Type II strains, Me49 and Prugniaud (Pru) are 
the most widely used laboratory strains and will be described in this thesis, are 
considerably less virulent, with a reported ld50 of around 100-1000 parasites 75, 76.   Type 
III strains are generally considered less virulent than type II strains although this is not 
necessarily true for all isolates 74. Overall, there is significant variability in the virulence 
of different strains of T. gondii that, as the next section will discuss, can affect the type of 
clinical disease presented by patients. 
 As previously noted, most human infections with T. gondii are asymptomatic and 
all three clonal lineages infect humans. It has long been considered that the strain of T. 
gondii could predict the type and/or severity of human disease 77, 78. Toxoplasmosis 
associated with HIV/AIDS has been shown to have a strong type II bias although the 
reason for this is not known 73, 77.  Conversely, ocular disease has primarily been 
associated with type I genotypes 79, 80.  The reasons for these disease variations are 
unclear, but there are numerous hypotheses for these observed differences.  Type I strains 
 11 
have been shown to replicate more quickly than type II strains in vitro but that has not 
been shown to be necessarily true in vivo 77. There are also suggestions that cells infected 
with type II strains migrate further than those infected with type I strains although type I 
strains may cross tissue barriers in vivo more readily 81-83.  Studies to determine whether 
these events dictate the differences observed in virulence have been thus far been 
inconclusive. 
From an immune perspective, there are additional important distinguishing factors 
between type I and type II strains that may affect host control.  It has been shown that 
type II strains elicit more protective IL-12 responses in vivo than type I 84.  Since IL-12 is 
required for resistance to T. gondii, this is an important observation that may indicate 
differences in how these parasites interact with the innate immune system.  Pru induces 
stronger DC and antigen-specific CD8+ T cell responses than RH; treatment of RH-
infected mice with IL-12 can restore these responses 85.  This disparity in IL-12 
production has recently been attributed to a the functions of a parasite kinase, ROP16 86, 
87, and while both type I and type II strains possess this kinase, the type I strain is able to 
phosphorylate the transcription factor Signal Transducer and Activator of Transcription 3 
(STAT3) more strongly than the type II ROP16.  This enhanced STAT3 activation has 
been associated with decreases in IL-12 and TNF-α production in vitro 87, 88.  This 
immune modulation will be discussed in more detail in a later section that details how T. 
gondii influences host-cell signaling.   However, it appears that multiple differences in 
rates of replication, motility, and host-pathogen interactions all contribute to the outcome 
of infection. 
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Immunity to T. gondii 
 While patients with immune-deficiencies highlight the need for T cells for control 
of T. gondii, the first evidence of protective immunity came as a consequence of a 
diagnostic clinical test for T. gondii identified by Sabin and Feldman in 1948 39, 89.  A 
serologic ‘dye test’, this assay provided for rapid diagnosis from blood of the presence of 
antibodies to T. gondii and allowed for advances in diagnostic epidemiology.  This 
included the ability to identify fetuses at risk for disease and individuals at risk for 
reactivation. While early studies focused on the antibody response to T. gondii, a 
powerful cell-mediated response to T. gondii was described by Frenkel in 1967 and this 
provided the foundation for subsequent studies 90.  The following section will describe 
the current understanding of innate and adaptive responses to T. gondii and Figure 2 
shows a model of the important cell types and immune molecules relevant to parasite 
control. 
 
Innate Immunity 
 Successful control of T. gondii requires innate responses that are important for 
directing effective adaptive responses.  Recognition of specific parasite proteins by 
accessory cells such as macrophages, dendritic cells (DCs), natural killer (NK) cells, and 
neutrophils is necessary for the innate response and functions through pattern recognition 
receptors (PRRs) such as toll-like receptors (TLRs) 2 and 11 91-95. T. gondii has many 
surface-bound and secreted antigens, such as cyclophillin 18 and profilin, that bind to 
cellular receptors which initiate a chain of signaling events that involve Myeloid 
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Differentiation primary response gene 88 (MyD88) and nuclear factor κB (NFκB) 
leading to production of TNF-α and IL-12 91, 96-99.  These cytokines are important for 
control; TNF-α is a potent agonist of the intracellular killing mechanisms of phagocytic 
cells such as macrophages 20, 100 while IL-12 acts primarily on NK and T cells to induce 
IFN-γ production 20, 100-102.   
IL-12 is produced by neutrophils 103, 104, macrophages, monocytes, and DCs 
following stimulation with T. gondii although some evidence suggests that conventional 
DCs (CD8a+) and plasmacytoid DCs (pDCs) are the major contributors 101, 105, 106, 107-111. 
IL-12 is composed of two subunits, p35 and p40, and p40-deficient mice are susceptible 
to acute toxoplasmosis 103, 112.  IL-12 is necessary during the first 3 days of T. gondii 
infection; treatment with IL-12 can rescue p40-/- mice but not if administered after day 3 
post-infection 17.  During these few first few days of infection, IL-12 induces NK cells to 
produce IFN-γ and become cytolytic and this initial wave of NK cell activity is thought to 
delay parasite replication until an effective adaptive response can be generated 103.  While 
NK cells can provide some resistance to T. gondii infection 102, long-term resistance is 
dependent on T cells and the IFN-γ secreted by T cells, and their cytolytic functions 15, 
113.   
 
Adaptive Immunity 
Proper activation of T cells is thought to require three signals.  Major 
histocombatibility complex (MHC) proteins present antigen to the cognate receptor on T 
cells. MHC loading of antigens comes in two flavors: MHC Class I is expressed by most 
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cells while MHC Class II is mainly expressed by professional APCS.  Proteins are 
sampled from both the extracellular milieu (MHC Class II) and intracellular 
compartments (MHC Class I) and these are converted into short peptides. The peptides 
loaded on Class I molecules are a general reflection of the repertoire of pathogen proteins 
but include many self-peptides as well 114.  Class II molecules are restricted to 
professional APCs and often present peptides from phagocytosed microbial products. The 
MHC-peptide complex then activates a T cell through its cognate T cell receptor (TCR) 
and provides the first signal 115.  Accessory cells that also express co-stimulatory 
molecules such as CD40, CD80, and CD86 provide a second signal to T cells through 
binding their cognate receptors such as CD28 116, 117. The third signal is IL-12 which 
polarizes CD4+ T cells to a Th1 phenotype that produces IFN-γ and promotes the 
expansion of CD8+ T cells to become IFN-γ-producing CTLs 118-121.   
This requirement for T cells to mediate immunity to T. gondii was highlighted 
during the 1980s, when the population of immune-compromised hosts grew dramatically 
as a result of the HIV/AIDS pandemic. Clinical observations of immune deficiencies 
leading to reactivation of toxoplasmosis was supported by studies in mice that showed 
that depletion of CD4+ or CD8+ T cells during chronic infection resulted in TE 15, 18, 122-
124. In addition to producing IFN-γ during toxoplasmosis, parasite-specific T cells also 
have the capacity to lyse infected cells in immunization and rechallenge models 125, 126, 
127, 128.  During toxoplasmosis, CD8+ CTL activity is partially dependent on the cytotoxic 
molecule perforin, particularly during chronic infection 129, 130, though there is evidence 
for perforin-independent pathways of lysing target cells 131, 132.  There are also reports 
that human CD4+ T cells can lyse T. gondii-infected cells 133, 134, but it is unclear whether 
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this occurs in the mouse.  Interestingly, though CTLs can lyse actively infected cells, 
these events do not appear to result in the death of the intracellular parasite 135. Together, 
these clinical observations and laboratory studies highlight the vital role for CD4+ and 
CD8+ T cells that produce IFN-γ in the long-term control of T. gondii 18. 
 Summarized in Figure 2, control of T. gondii infection requires the coordinated 
efforts of innate and adaptive responses.  Innate recognition in professional APCs occurs 
through stimulation of their pattern recognition receptors (PRRs).  This activation leads 
to production of pro-inflammatory cytokines such as TNF-α and IL-12 with the latter 
stimulating NK cells to produce IFN-γ.  IL-12 also enhances IFN-γ production from 
parasite-specific T cells to create a pool of activated antigen-specific effector T cells that 
control infection. IFN-γ activates anti-microbial responses that help restrain intracellular 
growth of T. gondii.  Together, the combination of innate cell production of IL-12 and T 
cell cytolytic activity and secretion of IFN-γ induces a strong Th1 immunity that 
effectively controls T. gondii replication and growth. 
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Figure 2. The innate and adaptive immune response to T. gondii. A. Innate cell 
populations such as neutrophils (Nφ), macrophages (Mφ), and dendritic cells (DCs) 
recognize T. gondii through TLRs and PRRs as they phagocytose parasites or become 
infected by them.  Activated cells then produce inflammatory cytokines such as TNF-α, 
that promotes intracellular killing, and IL-12. B. Secreted IL-12 is taken up by NK cells 
inducing IFN-γ production; IL-12 also synergizes with antigen-presentation to T cells to 
induce cytotoxic T cell responses and IFN-γ secretion. C. Activated NK cells and T cells 
produce IFN-γ which acts on infected cells to upregulate effector mechanisms.  D. Many 
cell types respond to IFN-γ to activate anti-microbial responses including all 
macrophages, neutrophils, and dendritic cells.  
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IFN-γ-dependent effector mechanisms and parasite killing 
As described in the previous section, NK and T cell production of IFN-γ is critical 
to control T. gondii.  The section will describe our current understanding of how IFN-γ 
mediates protection through upregulation of effector molecules and how this pathway 
synergizes with IFN-γ-independent mechanisms of killing such as CD40 ligation and 
autophagy.  It will highlight the cell types that are prominent “professional killers” of T. 
gondii such as the macrophage and neutrophil and how these phagocytic cell types 
mediate parasite clearance. 
Macrophages represent one of the major arms of the immune system and have an 
ability to kill intracellular microorganisms that is enhanced by IFN-γ 136.  Many early 
reports described the ability of macrophages to kill intracellular microbes such as T. 
gondii, Mycobacteria, and Leishmania 137-141. These studies identified that macrophages 
respond to IFN-γ to upregulate inducible nitric oxide synthase (iNOS) to produce of 
oxygen-free radicals mice, although humans lack this enzyme 142, 143. iNOS converts L-
arginine into nitric oxide (NO), which is an oxidative burst thought to damage DNA and 
limits rapid parasite replication .  In vitro studies in mice have demonstrated that NO can 
effectively kill parasites, or more precisely stall replication, leading to eventual clearance 
through other mechanism described in Figure 3.  However, although in vitro studies 
presented NO as a powerful mediator of parasite killing, it was unexpected that iNOS-/- 
mice were more resistant to T. gondii than IFN-γ-/- or IFN-γR-/- mice 144-147.  Since NO is 
required for chronic control but not acute control it suggests that mice have an additional 
IFN-γ-dependent, iNOS-independent mechanisms to control parasite growth 148.   An 
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insight into these mechanisms was provided by Taylor and colleagues who identified a 
critical role for a group of IFN-γ-dependent p47 Immunity-Related GTPases (IRGs) in 
resistance to T. gondii in mice 149. IFN-γ-inducible p47 IRGs were identified as critical to 
resistance to T. gondii as infected Irgm1-deficient mice succumbed acutely to infection 
with kinetics similar to IFN-γ knockout mice 150.  Similar reports using other similar 
IRGs such as Irgm1 and Irgm3 identified a group of proteins with unknown function that 
are required for resistance to a large number of pathogens including T. gondii, 
Trypanosoma cruzi, Leishmania major, Chlamydia trachomatis, Mycobacterium 
tuberculosis, Listeria monocytogenes, Salmonella typhimurium, and Legionella 
pneumophila 12, 14, 151-160. Twenty-three p47 IRGs have been identified in mice, some of 
which have a role in the control of distinct pathogens, but whose function is still poorly 
understood 160, 161.  Moreover, humans have only three described IRGs, one of which, 
Irgm1, has been directly linked with autophagic clearance of Mycobacteria 156, 161. The 
observation that humans have far fewer IRGs suggests that each may perform additional 
tasks, have a broader spectrum of activity, or that there are additional human orthologs 
161.  
How IRGs promote the control of T. gondii is not well understood. Studies have 
shown that some IRGs such as Irgm1 and Irgm3, colocalize to the parasitophorous 
vacuole and these events are associated with membrane stripping and characteristic 
autophagic membranes proximal to the damaged PV that could be blocked with inhibitors 
of autophagy 156, 161-166. Subsequent work by Subauste and colleagues demonstrated that 
an autophagy gene, beclin1, was required for CD40-mediated killing of T. gondii by 
macrophages in vitro 167, 168.  Another classical autophagy protein, atg5, was shown to be 
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linked to IRG functions as mice with a conditional deletion of atg5 in macrophages were 
acutely susceptible to T. gondii and Listeria monocytogenes 169.  Moreover, macrophages 
lacking atg5 protein were unable to load IRGs effectively and destroy the PV suggesting 
an intimate link between pathogen killing and autophagy. 
While the studies described above focus on the role of autophagy in killing 
mechanisms, there is also literature that suggests these events can influence the immune 
system. As highlighted in Figure 3, there is evidence that autophagy is involved in major 
histocompatibility complex (MHC)-restricted presentation of antigens and macrophages 
deficient in another IRG, Irgm3, are defective in their ability to present T. gondii antigen 
21.  Autophagic processing is also implicated in allowing intracellular Toll-like receptors 
(TLR) access to ingested material, and this may serve as a positive feedback 
mechanism in vivo to enhance antimicrobial effectiveness, although how this happens 
during any infection is unclear 170.   However, the current studies have not clearly 
delineated whether most autophagy proteins direct killing themselves, or if atg5 is unique 
in that has multiple functions 19, 168. 
In addition to studies with T. gondii, autophagy is implicated in resistance to other 
intracellular organisms including Listeria, Shigella, Mycobacterium, and herpes simplex 
virus-1 (HSV-1) 171-176.  That autophagy is needed in both Drosophila and mice for 
defense against Listeria monocytogenes suggests that this process is fundamentally 
important for multiple host species 176. This is further emphasized by the recognition that 
many microorganisms have evolved mechanisms to evade, control, or usurp basic 
autophagy pathways for their own survival. For example, some γ-herpes viruses encode 
proteins in their genomes that antagonize autophagy proteins 177, 178. This suggests that 
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tampering with this process may be an important determinant of pathogenicity relevant to 
numerous pathogen and that there is an important link between autophagy and IFN-γ 
responses in parasite killing, but how these pathways intersect in vivo remains an open 
question. 
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Figure 3.  The concerted actions of IFN-γ and autophagy in killing and disposal of 
intracellular pathogens.  IFN-γ binding to its cognate receptor (IFN-γR) induces 
upregulation of both nitric oxide that limits pathogen replication inducing a state of 
delayed replication or “stasis” and p47 IRGs (1) that are required for resistance to T. 
gondii. Autophagy activators, such as nutrient depletion, TLR stimulus, or T cell-
dependent CD40-CD40L ligation, activate atg5 (2) and the autophagic machinery that 
colocalize with the IRGs at the parasitophorous vacuole (3). Once at the pathogen-host 
interface, this complex induces vacuole degradation, lysosmal fusion, and autophagic 
clearance of the parasite (4). This process induces proteasomal degradation (5) and may 
allow subsequent loading of pathogen peptides onto MHC molecules for presentation to 
T cells (6). 
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IL-6 and T. gondii 
IL-6 is a pleiotropic cytokine with multiple functions during toxoplasmosis.  
Historically considered an inflammatory cytokine, infection of IL-6 knockout mice with 
T. gondii resulted in increased susceptibility to TE 179.  However, the pleiotropic nature of 
IL-6 was confirmed when chronically infected mice were treated with neutralizing 
antibodies to IL-6 and demonstrated reduced disease with fewer parasite cysts suggesting 
that IL-6 promoted parasite growth 180.  Recently, there has been renewed interest in the 
biology of IL-6 due to many new discoveries including the finding that IL-6 regulates the 
balance between Th17 cells and regulatory T cells (Tregs) 181-184.  Th17 is required for 
defense against several intracellular pathogens such as T. gondii, Yersinia pestis, 
Staphylococcus aureus, and Klebsiella 185-189. Additionally, IL-6 has been shown to be 
important for NK cell function, neutrophil recruitment, B cell differentiation, and DC 
maturation (Silver unpublished studies) 190-195.  Furthermore, IL-6 biology is complex and 
these studies described and those presented herein highlight some of the diverse functions 
that IL-6 plays during infection. 
 
Biology of IL-6 
 In 1968, T and B lymphocytes were discovered to play important roles in the 
production of antibody 196.  B cells were shown to produce antibodies but only when T 
cells were present and suggested that there was a secreted factor that stimulated growth 
and differentiation of B cells.  Subsequent studies on a cell line created from a patient 
with B cell leukemia identified this growth factor as IL-6, and it was confirmed to be the 
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same molecule as B-cell stimulatory factor-2 (BCSF-2), IFN-β2, 
Hybridoma/plasmacytoma growth factor, and hepatocyte stimulating factor (HSF) 197, 198.  
Subsequent studies using anti-IL-6 antibodies as well as IL-6 knockout mice were critical 
in identifying IL-6 as being involved in multiple pathways of inflammation, oncogenesis, 
and resistance to multiple infections 199-201. 
 While IL-6 and its biological effects have long been studied, it was the recent 
identification of IL-17-producing CD4+ T cells (Th17) and their role in inflammation that 
renewed interest in the cytokine 185-189.  IL-6 is an important mediator of the balance 
between Th17 cells and Tregs and drives IL-17 production from CD4+ T cells 181-184. 
Transforming growth factor β (TGF-β), was shown to induce regulatory T cells (Tregs) 
alone, but when combined with IL-6, TGF-β could induce Th17 cells 202-206. These two 
T-cell subsets have important immune functions: Th17 cell is involved in the 
pathogenesis of autoimmune diseases and protection against certain infections such as the 
Klebsiella and T. gondii, while Tregs control excessive effector T-cell responses and 
highlight the important functions of IL-6 and Th17 in immunity and immune-pathology 
207, 208. 
 
Clinical diseases associated with IL-6 
 Overproduction of IL-6 has been associated with multiple clinical diseases 
including rheumatoid arthritis (RA), Castleman's disease, juvenile idiopathic arthritis 
(JIA), and multiple myeloma 209-215.  Experimental animal models of RA using IL-6-
gene-deficient mice showed no increase in joint inflammation suggesting that IL-6 was 
important for inducing this disease.  Additionally, cultures of patient synovial cells 
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combined with their peripheral mononuclear cells demonstrated that osteoclast generation 
was inhibited by the addition of the anti-IL-6R antibody 216.  As a result, antibodies to the 
receptor to IL-6 (αIL-6R) were administered as a treatment for rheumatoid arthritis (RA), 
Castleman's disease, juvenile idiopathic arthritis (JIA), and multiple myeloma 209-215.  α-
IL-6R had been used experimentally since the 1990s but was approved for clinical use in 
the USA in 2010 under the name tocilizumab 217, 218. Overall, the positive clinical results 
from using tocilizumab have identified a beneficial effect of limiting IL-6-mediated 
inflammation for certain diseases. 
 
gp130 Signaling  
 Given the important role for IL-6 in immune function, considerable effort has been 
undertaken to understand how the signaling of IL-6 works. IL-6 and its family of 
cytokines which include IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-
1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF), neuropoietin 
(NPN), oncostatin M (OSM), IL-27, and IL-31 all utilize a receptor complex consisting 
of at least one gp130 signaling molecule (reviewed in 219). Gp130 was discovered in 
1978, and it is now appreciated that gp130 is associated with the signaling of a number of 
cytokines. Thus, when IL-6 binds to the IL-6R, it triggers a heterodimeric association 
with gp130 to form a signaling complex composed of a gp130 homodimer plus two IL-
6Rα chains.  The cytoplasmic domain of IL-6Rα is not necessary for signal transduction 
and the binding of IL-6 to its receptor triggers the association of IL-6Rα with gp130, 
leading to the formation of a hexamer composed of two each of IL-6, IL-6Rα and gpl30.  
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Gp130 is expressed by most cells in the body while IL-6Rα is mainly expressed by 
hepatocytes, neutrophils, monocytes/macrophages, and some lymphocytes. Additionally, 
a soluble form of the IL-6Rα (sIL-6Rα) is generated by either limited proteolysis of the 
membrane protein or translation from an alternatively spliced mRNA 220.  A unique 
property of IL-6, “trans-signaling,” as it has been termed, is possible as cells that express 
gp130 can respond to stimulation with IL-6 when co-cultured with sIL-6Rα 221-223.  One 
functional consequence of this is that infiltrating neutrophils can cleave the membrane 
IL-6Rα, thus generating the sIL-6Rα, allowing IL-6 to signal to local cells expressing 
only the gp130 subunit 221. Mice engineered to express soluble gp130 blocks IL-6 trans-
signaling and have defective inflammatory responses characterized by decreased 
infiltration of neutrophils and monocytes to the site of inflammation.   
 Stimulation of gp130 triggers the activation of three signaling cascades, most 
prominently the JAK-STAT pathway. A family of kinases located near gp130 on the cell 
surface called Janus kinases and include JAK1, JAK2, JAK3 and tyrosine kinase 2 are 
phosphorylated following receptor binding and activation. These enzymes then 
phosphorylate various STAT molecules, which allows these molecules to translocate to 
the nucleus and initiate gene transcription. Signaling through gp130 can activate STAT1, 
STAT3, and STAT5. Engagement of gp130 also leads to the recruitment of the 
cytoplasmic protein tyrosine phosphatase SHP2, which activates the Ras-ERK1/2 MAPK 
and PI3K/AKT pathways.  
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JAK/STAT signaling and the biology of SOCS proteins 
 Growth, differentiation, and other functions of immune and hematopoietic cells are 
controlled by multiple cytokines, which signal through cognate receptors. The Type I 
cytokines, which include those that use through gp130, signal in part through the 
JAK/STAT pathway and many of these signaling cascades are regulated by SOCS 
proteins.  Although these receptors often do not catalyze reactions themselves, they serve 
as docking sites for a family of kinases called Janus kinases (JAKs) 224.  Upon ligation, 
cytokines induce homo- or hetero-dimerization and activation of their receptors and 
induce the phosphorylation and activation of the JAKs, of which there are 4 known (JAK 
1-3, Tyk2) 225, 226.  Once activated, the JAKs phosphorylate the receptor, creating docking 
sites for SH2-containing signaling proteins, such as STATs, which in turn can be 
phosphorylated by the JAKs 226. As with many signaling cascades, there are feedback 
mechanisms that regulate cytokine-mediated JAK-STAT signaling that include 
dissociation of JAK/STAT proteins from the receptor complex, endocytosis and 
degradation of the receptor, and nuclear export of phosphorylated STAT molecules. 
However, Suppressors of Cytokine Signaling (SOCS) proteins are the primary negative 
regulators of JAK/STAT signaling 227, 228.  These proteins have similar homology to each 
other and tend to be specific for particular cytokine signaling cascades.  Many of these 
proteins are upregulated in settings of inflammation and infection. 
 Although initially described for Interferon signaling, JAK/STAT signaling has been 
observed for a number of cytokines, growth factors, and hormonal factors. Cytokines 
often induce the phosphorylation of multiple STAT molecules as well as other signaling 
proteins such as MAP kinsases, phosphatidyl-inositol-3 (PI3) kinase, and phospholipase 
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C-c (PLCc) 229-232.  Interactions between these signaling pathways are likely to 
differentiate between an IFN-γ-induced phosphorylation of STAT1 from an IL-6-induced 
phosphorylated STAT1 although this area is poorly understood. 
 Gene knockouts for many of these molecules have elucidated their biological 
functions. For example, JAK1-deficient mice cannot respond to a wide range of cytokines 
including those whose receptors utilize the common γ-chain and those that use gp130 233, 
234. JAK2 gene disruption causes embryonic lethality due to impaired erythropoiesis 
while JAK3 deletions causes severe immunodeficiency 235, 236. Mice that lack specific 
STAT proteins are viable but demonstrate abnormalities related to impairments in certain 
cytokines; for instance, STAT1 knockouts have impairments in IFN-mediated signaling 
237, STAT4 knockouts have a defect in IL-12 signaling 238, 239, and STAT6 knockouts 
cannot signal through IL-4 239. Thus, the combination of biochemical and genetic studies 
of STAT proteins has led to a more thorough understanding of how these molecules 
function. 
 
SOCS proteins 
 SOCS proteins were first identified through a genetic screen for inhibitors of IL-6 
signaling 240.  Currently, there are 8 known SOCS proteins in mice, numbered SOCS1-7 
plus the cytokine-inducible SH2 protein (CIS), these proteins have been shown to have 
important roles as negative regulators of multiple cytokines 241, 242.  These molecules are 
characterized by a central SH2 domain and a C-terminal 40-amino-acid module called the 
SOCS box.  Although they are similar in protein structure, they can have profoundly 
different functions in vivo. 
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 The proposed mechanisms of function for many of the SOCS proteins are described 
in Table 1.  CIS and SOCS2 can sterically hinder the STAT binding sites of receptors 
presumably using their SH2 domain as a pseudo-receptor 243-246. Nevertheless, based on 
studies using SOCS2-deficient mice 247, SOCS2 seems to be a relatively specific negative 
regulator of the GH−STAT5 pathway. SOCS5 has been proposed to inhibit IL-4 
signaling by interacting with the IL-4Rand inhibiting binding of JAK1 248.  Both SOCS1 
and SOCS3 can inhibit JAK tyrosine kinase activity through a kinase inhibitory domain 
(KIR) located within the N-terminal domain, which either prevents binding directly or 
acts as a pseudosubstrate 249-251. SOCS1 uses its SH2 domain to directly bind the 
activation loop of JAKs and binds the catalytic pocket of JAKs through its KIR 251. As 
SHP-2 can promote gp130 signaling through the activation of MAP kinases, SOCS3 may 
also suppress gp130 signaling by competing with SHP-2 for the receptor although it is 
possible that SHP-2, a phosphatase, may negatively regulate gp130 signaling by 
dephosphorylating the associated JAKs 252-254.  Additionally, SOCS proteins have a 
SOCS box which has been shown for some of the SOCS family members to interact with 
ubiquitination molecules elongins B and C, cullins, Rbx-1 and E2 to function as an E3 
ubiquitin ligases and mediate the degradation of proteins associated through their N-
terminal regions 255-258. Therefore, SOCS proteins seem to combine targeted inhibition of 
JAKs and STATs with a general mechanism of proteasomal degradation for intended 
substrates. Interestingly, the SOCS box is also important for the stabilization and/or 
degradation of the SOCS1 and SOCS3 proteins themselves as interaction of the SOCS 
box with elongin C stabilizes SOCS3 protein expression whereas phosphorylation of the 
SOCS box enhances proteasome-mediated degradation of SOCS3 255-258. The role that the 
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SOCS box plays in other SOCS proteins remains unclear. 
 
SOCS3 regulates signaling through gp130  
 Many cytokines activate STAT3, including IL-6 and IL-10, yet they yield unique 
patterns of transcription and biological functions but it was unclear how STAT3 signals 
could be differentially regulated.  Historically, IL-6 has been considered a pro-
inflammatory cytokine as it played a prominent role in many inflammatory and 
autoimmune diseases, while IL-10 is an immunoregulatory cytokine that has potent anti-
inflammatory activity, including the suppression of TLR activation and NF-κB-mediated 
genes 259-266. While it was known that STAT3 is essential for the biological actions of 
both IL-6 and IL-10, it was unclear how the two STAT3 signals could be differentiated to 
provide such polar opposite functions.  In 2003, SOCS3 was shown to provide at least 
one possible mechanism for how this was possible 267.  Both IL-6 and IL-10 activate 
STAT3 however only IL-6 does so through use of the gp130 subunit.  In a study by 
Yasukawa et. al., it was shown that the inhibitory effects of SOCS3 are due to its ability 
to specifically bind to the phosphorylated tyrosine residue 759 on gp130 and that this 
binding led to an inability of STAT3 to dock and/or be phosphorylated following receptor 
stimulation 267.  As SOCS3 is upregulated by both IL-6 and IL-10, the researchers 
observed that the preferential binding of SOCS3 to the IL-6R limited its response and this 
provided the mechanism for observed differences in signaling between the cytokines as 
IL-6 and IL-10 function.  More precisely, in the absence of SOCS3, IL-6 had has 
phenotypically similar inhibitory properties as IL-10.  Additionally, injection of SOCS3 
conditionally-deleted mice with a lethal dose of LPS led to survival of the mice 
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associated with impaired TNF-α and IL-12 responses 267.  This suggested that SOCS3 
specifically acted on IL-6 signals during inflammation and was a strong inhibitor of its 
inflammatory properties although very little was understood about what this meant in 
vivo.   
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Protein Phenotype of knockout mice Cytokines  Mechanism of regulation 
SOCS1 Severe inflammation, neonatal death IFN-γ 1,3,4 
SOCS2 Gigantism GH, IGF, 
PRL, IL-2, 
IL-3, EPO, 
LIF, EGF, 
leptin and 
IFN-α 
1,2 
SOCS3 Defects in erythopoiesis, embryonic lethal gp130, LIF, 
leptin 
1,2? 
SOCS4 None/unknown EGF 2 
SOCS5 Unknown, possible T cell defects STAT6 Unknown 
SOCS6 Mild growth retardation IGF 2 
SOCS7 None/unknown IGF Unknown 
CIS Hematopoietic deficiencies EPO, IL-3 1,4 
 
 
 
Table 1.  List of phenotypes associated with SOCS gene deletions.   Listed are the 
eight known SOCS proteins, their phenotype in knockout mice, the cytokines believed to 
be involved or regulated by the particular SOCS protein and the proposed mechanism of 
action by which it exerts its regulatory effect.   1. Inhibition of STAT protein binding 
either by steric hindrance of STAT binding.  2.  Ubiquitination of JAK, STAT, or another 
directly involved protein.  3. Inhibition of the JAK kinase activity through use of its KIR 
or kinase inhibitory region.  4. Acts as a psuedoreceptor for docking of STAT proteins. 
 
GH: Growth Hormone; IGF: Insulin Growth Factor; PRL: Prolactin; EPO: 
Erythropoietin; LIF: Leukemia Inhibitory Factor; EGF: Epidermal Growth Factor 
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II.  
 
The Role of Macrophage STAT3 Signaling in  
Resistance to T. gondii 
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Abstract 
 Resistance to the intracellular parasite Toxoplasma gondii is dependent upon 
interferon-γ (IFN-γ) signaling which upregulates an array of genes involved in anti-
microbial immunity. These genes encode both pro-inflammatory cytokines and effector 
molecules that allow infected cells to kill this pathogen.  T.gondii has developed multiple 
mechanisms to evade this response including the ability to activate STAT3 in host cells 
that inhibits inflammatory processes.  Recent studies have described this phenomenon; 
identifying a secreted parasite kinase, ROP16, as the protein responsible for direct 
phosphorylation of STAT3 resulting in inhibition of pro-inflammatory cytokines, 
particularly IL-12.  Other studies have suggested that this STAT3 activation was strain-
dependent and might provide a mechanism for virulence differences in vivo.  
Additionally, it was hypothesized that removal of STAT3 from macrophages would 
eliminate a pathway that promotes parasite replication leading to enhanced resistance in 
vivo.  Data provided here indicate that macrophages lacking STAT3 produce similar 
levels of pro-inflammatory cytokines and mice with a deletion of STAT3 in macrophages 
(LysM-cre Stat3fl/fl) have comparable resistance to wild type mice when infected..  These 
data suggest that parasite-induced STAT3 signaling in macrophages may not be as 
critical to resistance to T. gondii as previously considered. 
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Introduction 
T. gondii has many mechanisms to interfere with host-cell signaling that includes 
its ability to interfere with STAT1 and NF-κB signaling as well as to induce the 
phosphorylation of STAT3 268-270. Several studies have described this latter phenomenon, 
suggesting that T. gondii releases the rhoptry kinase ROP16 upon infection to directly 
phosphorylate STAT3 86, 87, 270, 271.  Since STAT3 is the predominant transcription factor 
for the anti-inflammatory cytokine IL-10, it was hypothesized that these events induced 
an IL-10-like transcriptional profile that would restrict inflammatory responses from 
macrophages.  As a result of these combined efforts, infection of a macrophage by T. 
gondii would impair STAT1 and NF-κB signaling making the cell less responsive to 
IFN-γ and TLR stimuli and also induce the anti-inflammatory responses driven by 
activation of STAT3.  
Previous studies showed that T. gondii induces the rapid phosphorylation of 
STAT3 that correlates with a reduction in the ability of these macrophages to produce 
TNF-α and IL-12p40 87, 270.  It was also reported that the avirulent strain Prugniaud (Pru), 
but not the more virulent RH strain, induced the production of IL-12p40 from resting 
macrophages 87. Work from other groups suggested that the Pru does not activate STAT3 
as efficiently as RH does and this underlines the disparity in IL-12 production which 
might account for the observed differences in virulence 87, 272. Data presented here 
demonstrate that despite basal differences in IL-12 production from infected 
macrophages, Pru phosphorylated STAT3 in macrophages similarly to RH and both 
strains were able to inhibit pro-inflammatory cytokines from macrophages equally.   
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Although no in vitro differences in STAT3 signaling between parasite strains 
could be observed, studies showed that a secreted rhoptry protein (ROP16) was a key 
virulence factor that could directly phosphorylate STAT3 upon injection in a cell 86, 87, 272.  
Additionally, when transgenic mutants were made by overexpressing ROP16 from a less 
virulent strain in RH, virulence could be attenuated and this was associated with 
increased IL-12 production 87.  These results supported the hypothesis that STAT3 
signals in vivo were important for T. gondii virulence by limiting the protective IL-12 
response.  However, when mice containing a conditional deletion of STAT3 in 
macrophages and neutrophils (LysM-cre Stat3fl/fl mice) were infected, no detectable 
difference in IL-12 production or IFN-γ production was found. However, during the 
chronic phase of infection, parasite DNA in the brain was lower in LysM-cre Stat3fl/fl 
mice than control Stat3fl/fl mice although survival was similar. These data suggest that 
STAT3 in macrophages is not required for resistance to T. gondii in vivo.  Surprisingly, 
despite observed in vitro differences, the loss of STAT3 in macrophages did not lead to 
increased IL-12 concentrations in vivo indicating that T. gondii may target IL-12 from 
other cell types or that the increased macrophage-activation predicted by removal of 
STAT3 does not affect overall IL-12 production. 
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Materials and Methods 
Mice and infections 
LysM-cre Stat3fl/fl mice were originally generated by Peter Murray as previously 
described 270.  C57/Bl6 mice were obtained from Taconic Farms Inc (Germantown, NY). 
C57/Bl6, Socs3fl/fl, and LysM-cre Stat3fl/fl mice were bred in the University Laboratory 
Animal Resources facilities at the University of Pennsylvania. All procedures were 
performed in accordance to the guidelines of the University of Pennsylvania Institutional 
Animal Care and Use Committee.  RH and Prugniaud (Pru) parasites were grown in 
Human Foreskin Fibroblast (HFF) monolayers cultured with D10 media (DMEM, 25% 
M199 Supplement, 10% Fetal Bovine Serum, 0.5% penicillin/streptomycin (10,000 
µg/mL), 0.5% gentamycin (50 µg/mL)) and harvested as previously described 273. Bone-
marrow derived macrophages (BMMφ) were flushed from mouse femurs and grown for 6 
days in DMEM containing 1% sodium pyruvate, 1% penicillin/streptomycin, 10% FBS, 
30% L929 cell supernatant, and 1% HEPES 269, 273.  All infections were performed i.p. 
with 104 parasites.  
 
Immunoblotting 
106 BMMφ were cultured in 96 well plates overnight and then infected with 5:1 Pru 
parasites for the indicated durations.  Lysates were prepared using TNT buffer (0.1 M 
Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20) combined with complete protease 
inhibitors (Roche, Mannheim, Germany) at 1:100 for 20 minutes on ice and then stored at 
-20°C.  Samples were electrophoresed and transferred to Immobulon-P membrane 
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(Millipore, Bedford, MA) and blocked for 1 hr in 5% nonfat dry milk and probed 
overnight with mouse monoclonal antibodies to SOCS3 (Invitrogen, Carlsbad, CA), β-
actin, pSTAT3, and total STAT3 (Cell Signaling, Danvers, MA).  Blots were washed in 
TBS-Tween 3 times and probed with α-mouse or α-rabbit secondaries conjugated to 
horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA) at 1:10,000 for 1 hr 
at room temperature.  Blots were washed 3 times and developed with enhanced 
chemiluminescence and exposed to film.  Results are representative of two independent 
experiments. 
 
Cytokine and flow cytometric analysis 
Whole splenocytes were washed and resuspended in complete RPMI 1640 (Invitrogen) 
containing 10% FBS (Serum Source International), 1% penicillin/streptomycin 
(Invitrogen), 1 mM sodium pyruvate (Mediatech, Manassas, VA), 2 mM L-glutamine 
(Mediatech), 0.1% 2-mercaptoethanol (Invitrogen) before being plated at a cell density of 
106 cells per well in a final volume of 200 µl in 96-well plates (Costar, New York). Cells 
were stimulated with or without soluble Toxoplasma antigen (STAg) at 50 µg/mL, or α-
CD3 at 1µg/mL (eBioscience) for 24 hr at 37 C in 5% CO2. Brain mononuclear cells 
(BMNCs) were isolated as previously described 274, 275. Perfused brains were cut into 
small pieces, passed through an 18 gauge needle, and digested with collagenase/dispase 
and DNase (Roche) for 90 min. Following the digestion, the cells were washed and 
strained through a 70 µm filter. Subsequently, cells were resuspended in 60% percoll, 
overlayed with 30% percoll, and centrifuged at room temperature for 25 min at 2000 rpm. 
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BMNCs were collected from the interface, washed, and enumerated. For T cell recall 
responses, splenocytes were plated at 500,000 cells/well and BMNCs at 200,000 
cells/well. Peritoneal cells were isolated as previously described 25 and cell-free 
peritoneal wash fluid was used for cytokine analysis. Concentrations were normalized to 
the amount of peritoneal fluid recovered from each mouse. Blood was collected via 
cardiac puncture.  Concentrations of IFN-γ, IL-12p40, and IL-6 were determined by 
ELISA using antibodies from eBioscience (San Diego, CA).  Freshly isolated PECs from 
infected mice were incubated with Fc block (0.1 µg/mL 24G2 antibody) for 15 min prior 
to surface staining with Ly6C-PerCP 5.5 (HK1.4), CD11b-FITC (M1/70), F4/80-eFluor 
780 (BM8), GR1-PECy7 (RB6-8C5), CD86-APC (16-10A1), CD80-PE (GL1), NK1.1-
PE (PK136), CD4-eFluor 780 (RM4-5), CD8-PerCP 5.5 (53-6.7), CD19-PECy7 
(eBio1D3 (1D3)), CD11c-APC (N418), CD62L-APC (MEL-14), and CD44-PE (IM7) 
(eBioscience, San Diego, CA), MHC Class II I-A/I-E (Biolegend, M5/114.15.2), CD3ε-
Pacific Blue (500A2), and CD19-Pacific Blue (1D3) (BD Biosciences). 106 PECs were 
plated in RPMI 1640 and stimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) 
in the presence of brefeldin A (10 µg/mL) (Sigma) for 4 hrs at 37 °C with 5% CO2 unless 
otherwise noted. The cells were fixed with 2% paraformaldehyde following surface stain. 
(Electron Microscopy Science, Hatfield, PA) for 10 min. For intracellular staining, the 
cells were permeabilized with 0.5% saponin (Sigma, St. Louis, MO) and stained with 
anti-IFN-γ-APC (XMG1.2) or IL-12p40-APC (17.8) (eBioscience). All flow cytometry 
was performed on a FACSCanto using FACSDIVA 6.0 software (BD Biosciences, San 
Jose, CA). Analysis was performed using FlowJo software (Treestar Inc., Ashland, OR).  
Experiments were performed twice with similar results. 
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In vitro killing assay and inhibition assays 
5x105 BMMφ were harvested and cultured in 96 well plates and pretreated overnight with 
media alone or IFN-γ  (BD Biosciences, San Jose, CA) and TNF-α (eBioscience) at 
indicated concentrations. Cells were infected with Pru at 1:1 and incubated overnight.  
Cells were then centrifuged onto microscope slides and the number of infected 
macrophages was counted.  Nitrite analysis was performed using the Griess protocol 276.  
Briefly, 50µl of sample was added to equal volume of a mixture (1:1) of 1% 
sulfanilamide and 0.1% naphthylethylenediamine in 2% (vol/vol) phosphoric acid. After 
incubation at room temperature, the optical density of the reaction product was measured 
at a wavelength of 540 nm and the nitrite concentration was calculated with sodium 
nitrite as a standard.  For parasite cytokine-inhibition assays, 2x105 BMMφ were plated 
and infected with either RH or Pru parasites at an MOI of 1:1 for 1 hr prior to LPS 
stimulation (100 ng/mL, Sigma) for 24 hours.  For IL-6 inhibition assays, BMMφ were 
stimulated with IFN-γ (10ng/mL) and LPS (10ng/mL) with or without IL-6 (10 ng/mL) at 
10 fold increments beginning at 0.001 ng/mL (eBioscience) or α-IL-6 (100 ng/mL, 
BioXcell).  ELISAs of supernatants from 24 hr cultures were performed using antibodies 
for IL-12p40 and TNF-α (eBioscience). 
 
Statistical analysis 
Statistical analysis was conducted Students’ t test or One-Way ANOVA and correlations 
were calculated with Prism software (Graphpad Software).  
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Results 
T. gondii induces strain-independent phosphorylation of STAT3 in 
macrophages  
 Many genotypic differences have been suggested to account for variances in 
virulence observed between the three clonotypic strains of T. gondii.  Recently, it has 
been described that virulent Type I strains induce the phosphorylation of STAT3 more 
prominently than Type II strains and subsequently could inhibit IL-12 production more 
effectively 87, 271.  This idea was supported by data that showed that the ROP16 molecule 
of a type I strain, RH, elicited a more robust phosphorylation of STAT3 associated with 
lower IL-12 responses when transferred to a type II, Pru. However, these studies 
measured pSTAT3 in a fibroblast cell line rather than primary macrophages where the 
IL-12 was measured 87.  In order to address whether type I strains truly had better 
inhibitory qualities than type II strains in vitro, the kinetics of STAT3 signaling and 
subsequent IL-12 production was assayed using ΒΜΜφ. 
 To determine if there were strain-specific differences in the ability of T. gondii to 
phosphorylate STAT3 in macrophages, ΒΜΜφ were infected with RH and Pru at an 
M.O.I. of 5:1. Phosphorylated STAT3 was identified by western blot at 30 minutes post-
infection for both RH and Pru and remained detectable for up to 4 hours (Figure 4A).  
These data suggested that Pru phosphorylates STAT3 similarly to RH yet only Pru can 
elicit IL-12 from otherwise unstimulated macrophages.  When ΒΜΜφ were infected for 
24 hours with either strain, Pru elicited significantly greater IL-12p40 production than 
RH (p<0.001)  (Figure 4B).  This was the only pro-inflammatory molecule that was 
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detected in the supernatants of BMMφ infected with RH or Pru as TNF-α, IL-6, nitric 
oxide (NO), IL-10, CCL3, CCL4, or CCL5 production could not be observed (data not 
shown).  These data suggest that either Pru promotes the production of IL-12p40 or that 
RH has an additional mechanism to suppress IL-12p40 that the avirulent Pru lacks.  
 Phosphorylation of STAT3 by T. gondii is associated with the inhibition of pro-
inflammatory responses by activated macrophages.  To determine if Pru can inhibit 
macrophage responsiveness similarly to RH, ΒΜΜφ were infected for 1 hr with either 
strain or given soluble toxoplasma antigen (STAg) as a followed by 24hrs of LPS 
stimulation.  Infection with either strain dramatically reduced the ability of macrophages 
to produce IL-12p40, TNF-α, IL-6, or NO (Figure 4C).  STAg stimulation had significant 
effects on TNF-α but these were not as prominent as with live parasites while STAg 
stimulation also significantly enhanced nitrite production following stimulation (Figure 
4C).  STAg also induced no significant change in IL-12p40 or IL-6 that suggest that live 
parasites are more efficient inhibiters of cytokine production.  IL-10, however, was not 
shown to be upregulated following LPS stimulation alone, but enhanced following RH 
and STAg stimulation (p<0.05) (Figure 4D).  Curiously, Pru seemed to have no effect on 
IL-10 production. This supports data published suggesting that infection with RH does 
not interfere with overall protein translation or secretion but rather specifically targets 
certain genes for downregulation (i.e. IL-12p40) while upregulating other anti-
inflammatory genes (i.e. IL-10) 277.  No difference in chemokine production was found 
between the two strains for CCL3, CCL4, and CCL5 following LPS stimulation (Figure 
4E). These data suggest RH and Pru have similar mechanisms to downregulate certain 
pro-inflammatory responses while RH has additional mechanisms that alter IL-12p40 and 
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IL-10 responses.  Previous studies indicated that RH inhibited TNF-α and IL-12p40 in a 
STAT3-dependent manner 270, therefore it implies that the ability of RH to inhibit NO 
and IL-6 is also STAT3-dependent although these experiments were not performed.  
However, it is interesting that Pru, which here has very similar effects on these cytokines 
as RH, was shown to phosphorylate STAT3 just as effectively as RH, which contradicts 
previous studies 87. Therefore, further investigation is required to determine if the effects 
of the parasites on IL-6, NO, and IL-10 are also STAT3-dependent. 
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Figure 4.    Pru but not RH induces IL-12p40 from unstimulated macrophages while 
both strains phosphorylate STAT3 and limit pro-inflammatory cytokine release 
from activated macrophages.  RH was shown to more strongly phosphorylate STAT3 
in fibroblasts than Pru and this was associated with diminished IL-12 responses. In order 
to determine if type I and type II strains of T. gondii affect STAT3 signaling and cytokine 
production differently, BMMφ were incubated with either strain of the parasite and cells 
were measured for phosphorylation of STAT3 or cytokine production. A) Both RH and 
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Pru induced the phosphorylation of STAT3 by 30 minutes post-infection of unstimulated 
macrophages.  The signal diminished for STAT3 by about 4 hours for both strains of 
parasites and is nearly absent by 24 hrs.   B) RH and Pru were incubated with bone-
marrow macrophages and the supernatants were measured for IL-12p40 after 24 hrs.  RH 
induced a non-significant increase in IL-12p40 concentration that was much lower than 
Pru (p<0.01). C) RH and Pru inhibited pro-inflammatory cytokine release from LPS-
stimulated macrophages.  Cells were infected for 1 hr and then stimulated for 24 hrs with 
LPS (100 ng/mL) and measured for cytokine production.  STAg was used as a control for 
live parasites.  Both strains of parasite were able to impair TNF-α, IL-12p40, NO, and 
IL-6 production from macrophages while STAg largely could not.  D) RH enhanced IL-
10 production from stimulated macrophages suggesting that its inhibitory actions are 
specific for pro-inflammatory molecules. E) Neither RH nor Pru affected the production 
of the chemokines CCL3, CCL4, and CCL5 from LPS-stimulated macrophages 
indicating that the inhibitory properties of T. gondii are specific for certain pro-
inflammatory molecules but not others.  Experiements were repeated twice with similar 
results.  Mean +/- SD.  Western blots were performed by Carolyn M. Gray. 
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STAT3 is not required for induction of IL-12 by Pru 
 Previous studies identified a role for STAT3 in inhibiting IL-12 production from 
macrophages infected with T. gondii independently of IL-6 and IL-10 87, 270. These 
studies suggested that RH more efficiently phosphorylated STAT3 than Pru in order to 
reduce pro-inflammatory cytokine production and that these effects caused the observed 
in vivo differences in virulence.87. Figure 4 demonstrated that Pru phosphorylates STAT3 
as effectively as RH upon infection but that only Pru induced IL-12p40 from 
unstimulated macrophages.  To determine if this difference in IL-12p40 production was 
STAT3-dependent, control and STAT3-deficient macrophages were infected with either 
RH or Pru for 24 hours and the supernatant cultures were measured for IL-12p40.  As 
shown in Figure 5A, Pru but not RH induces the production of IL-12p40 from 
macrophages for both control and STAT3-deficient macrophages.  This suggests that 
when STAT3 is absent, there is still a difference between RH and Pru in the production 
of IL-12p40 from macrophages. 
 Binding of IL-10 to its receptor leads to the phosphorylation of STAT3 and this 
activation is associated with the inhibitory functions of this cytokine.  Therefore, in the 
absence of STAT3 in macrophages, it is conceivable that these cells may display 
enhanced pro-inflammatory properties such as increased IL-12 or TNF-α production as 
endogenous IL-10 cannot signal.  To directly assess this, control and STAT3-deficient 
BMMφ were analyzed for their ability to produce these cytokines when stimulated with 
IFN-γ and LPS.  Curiously, there was no increase in production of either IL-12 and TNF-
α following stimulation of STAT3-deficient macrophages as compared to wild type 
macrophages (Figure 5B).  This suggested that STAT3 may not be required for inhibition 
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of these responses although with controlling for other inhibitory cytokines in the culture 
such as IL-10, it is difficult to conclude that these effects are STAT3-independent. 
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Figure 5.  Macrophages deficient in STAT3 produce comparable pro-inflammatory 
cytokines as wild type macrophages.  BMMφ do not require STAT3 for production of 
IL-12p40 following Pru infection or the production of IL-12p40 and TNF-α from 
stimulated macrophages.  2.5x105 BMMφ were infected with RH or Pru for 24 hours and 
the supernatants were measured for IL-12p40 (n=3).  A) Pru induced a higher 
concentration of IL-12p40 from control macrophages than RH (p<0.05).  Macrophages 
deficient in STAT3 (LysM-cre Stat3fl/fl) produced similar concentrations of IL-12p40 
following infection with either strain suggesting that STAT3 is not required for this 
phenomenon. Mean +/- SD. B) BMMφ were stimulated with IFN-γ (100 Units/mL) and 
LPS (100ng/mL) for 24 hours and supernatants were measured for TNF-α and IL-12p40 
by ELISA.  STAT3 macrophages produced similar levels of cytokine following 
stimulation as control macrophages. Results are indicative of two independent 
experiments.   
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LysM-cre Stat3fl/fl mice are resistant to T. gondii 
 The in vitro studies described in the previous sections suggest a limited role for 
STAT3 in macrophages in vivo. However, macrophages receive multiple inflammatory 
stimuli following infection and it is conceivable that these pro-inflammatory signals have 
in vivo consequences that are not observed in these culture conditions.  Although these 
data suggest otherwise, evidence from the literature suggest that infection of LysM-cre 
Stat3fl/fl mice would lead to a phenotype that reflected the ability of these mice to induce 
enhanced Th1 responses with more efficient control of parasites 86, 87, 270.  However, when 
Stat3fl/fl and LysM-cre Stat3fl/fl mice were infected i.p. with the lethal RH strain at a low 
dose of 103 parasites i.p., all mice succumbed to infection by day 8 (Figure 6A).  
Additionally, a less virulent RH strain that expresses the Pru ROP16 (RH-Rop16) was 
used to infect these mice with a high dose (1000 cysts, data not shown) or a low dose 
(500 cysts, Figure 6B) administered by oral gavage and there was no significant 
difference in mortality.  These data suggest LysM-cre Stat3fl/fl mice do not show enhanced 
resistance to the more virulent strains or high doses of T. gondii. 
 Type II strains cause lethal inflammation in IL-10 knockout mice, therefore it was 
hypothesized that infection of LysM-cre Stat3fl/fl mice with Pru or Me49 might have 
similar consequences 26.  Stat3fl/fl and LysM-cre Stat3fl/fl mice were infected i.p. with Pru 
(Figure 6C) and both intraperitoneally (data not shown) and by oral gavage (Figure 6D) 
with Me49.  None of these infections produced differences in mortality and all mice 
survived challenge out to 50 days.   
LysM-cre Stat3fl/fl mice demonstrate similar resistance to T. gondii compared to 
wild type mice in terms of survival, but the literature suggested that markers of 
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inflammation might be enhanced in these mice 270.  At 10 days post infection with Pru, 
very few parasites could be identified in the peritoneum of Stat3fl/fl and LysM-cre Stat3fl/fl 
mice (data not shown). The total number of peritoneal cells was appeared greater in 
LysM-cre Stat3fl/fl than control Stat3fl/fl mice but this was just above the level for 
consideration of statistical significance (p=0.06) while the total number of spleen cells 
was similar between groups of mice (Figure 7A,B).  This suggested that LysM-cre 
Stat3fl/fl mice have greater inflammatory response during acute infection. STAT3 
activation is associated with an impairment of pro-inflammatory responses from 
macrophages, therefore, the production of pro-inflammatory cytokines was measured 
from mice acutely infected with T. gondii. However, in LysM-cre Stat3fl/fl mice there was 
comparable IL-12p40 or IFN-γ production in the serum of mice infected for 10 days 
(Figure 7C).  Curiously, IL-10 production was significantly decreased in the sera of 
LysM-cre Stat3fl/fl compared to control mice and supports data that IL-10 positively 
regulates its own production in a STAT3-dependent manner (Figure 7D) 278.  
Surprisingly, although there was diminished IL-10, this did not lead to more prominent 
changes in the inflammatory response.  Given the prominent role that STAT3 plays in 
macrophages in vitro, it was surprising that at some level, these mice did not show 
enhanced inflammation as evidenced by increased mortality.   However, further 
investigation would be required to strengthen the conclusion that STAT3 in macrophages 
does not reduce inflammation in vivo.  
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Figure 6. LysM-cre Stat3fl/fl mice show no significant difference in mortality 
compared to wild type mice for multiple infection models of T. gondii. To determine 
if LysM-cre Stat3fl/fl mice are hyper-resistant to both virulent and avirulent strains of T. 
gondii, oral and intraperitoneal infectious were performed with multiple strains of T. 
gondii.  A) 5 mice per group were infected with a low dose of RH (103 parasites) 
intraperitoneally and monitored for survival.  All mice succumbed to infection by day 8 
p.i. B) Using a mutant of ROP16 in RH that reduces virulence and allows the parasite to 
form brain cysts, 5 mice per group of control and LysM-cre Stat3fl/fl were infected by oral 
gavage with 500 cysts and monitored for survival.  A large proportion of both groups 
succumbed to infection by around day 15 with a few wild type mice surviving past 20 
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days. C-D) 5 mice were group were infected intraperitoneally with 104 Pru (C) or by oral 
gavage with 50 cysts of Me49 (D) and monitored for survival.  All mice in both groups 
survived the duration of the experiment.  Results are indicative of two independent 
experiments. 
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Figure 7. LysM-cre Stat3fl/fl mice have similar levels of IL-12p40 and IFN-γ  despite 
diminished IL-10 production during acute infection.  To determine if pro-
inflammatory responses are heightened in LysM-cre Stat3fl/fl mice, the numbers of PECs 
and splenocytes were counted as well as the sera from Stat3fl/fl (n=5) and LysM-cre 
Stat3fl/fl mice (n=5) infected for 10 days was analyzed for total cellularity and cytokine 
production. A) The total number of cells recovered from the peritoneum of infected mice 
was greater in LysM-cre Stat3fl/fl mice although this was not considered statistically 
significant.  B) The total number of splenic cells of Stat3fl/fl and LysM-cre Stat3fl/fl mice 
was comparable at day 10 p.i. C,D) IFN-γ and IL-12p40 concentrations in the sera were 
found to be comparable despite lower levels of IL-10.  Mean +/- SD.  Two independent 
experiments were performed with similar results. 
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LysM-cre Stat3fl/fl mice have lower parasite burdens despite similar inflammatory 
responses during chronic T. gondii infection 
 To determine if chronic infection was altered in LysM-cre Stat3fl/fl mice, these and 
control mice were orally infected with 20 cysts of Me49 and sacrificed at day 43 for 
parasite burden and analysis of the inflammatory response.  At this time point, there was 
significantly lower parasite DNA in the brains of LysM-cre Stat3fl/fl mice than Stat3fl/fl 
mice (Figure 8A).  Despite this reduction, cysts could still be observed in the brains of 
LysM-cre Stat3fl/fl mice while very little pathology was apparent in either genotype 
(Figure 8B).  This reduced parasite burden was associated with comparable populations 
of splenocytes and brain mononuclear populations (Figure 8C).  Moreover, there was no 
increase in total CD4+ or CD8+ T cells in LysM-cre Stat3fl/fl mice that might explain the 
lower parasite burdens (Figure 8E).  CD4+ T cells were also similarly activated 
(CD62Llow, CD44hi) between Stat3fl/fl and LysM-cre Stat3fl/fl mice (Figure 8F).  Moreover, 
there was no difference between genotypes for the production of IFN-γ, IL-10, or IL-17 
from CD4+ T cells isolated from the brains of infected mice.  These data suggest that the 
reduction in parasite burdens occurred early during infection and was not due to 
enhanced T cell responses. 
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Figure 8. LysM-cre Stat3fl/fl mice have similar inflammatory responses yet lower 
parasite burdens in the brain during chronic T. gondii infection.  To determine if 
LysM-cre Stat3fl/fl mice have stronger pro-inflammatory responses following T. gondii 
infection, Stat3fl/fl and LysM-cre Stat3fl/fl mice (n=5 per group) were infected with 20 cysts 
of Me49 intraperitoneally and sacrificed at day 43 post-infection.  A,B) Brain samples 
were taken and analyzed for parasite DNA (A) and pathology (B).  LysM-cre Stat3fl/fl 
mice had significantly lower parasite burdens than control mice despite similar 
pathology.  Cysts were identified in LysM-cre Stat3fl/fl mice, although rare, indicating that 
sterile clearance was not achieved. C,D) Total number of recovered splenic (C) and brain 
 57 
(D) cells showed no significant difference between control and LysM-cre Stat3fl/fl mice.  
E) There was no difference between control and LysM-cre Stat3fl/fl mice in the total 
number of CD4+ and CD8+ T cells in the brain although there is a trend toward fewer T 
cells.  F) Stat3fl/fl and LysM-cre Stat3fl/fl mice had similar levels of naïve (CD62Lhi, 
CD44low) and activated (CD62Llow, Cd44hi) CD4+ T cells at day 43 post-infection. G) 
Control and LysM-cre Stat3fl/fl mice had similar numbers of IFN-γ-, IL-10- and IL-17-
producing CD4+ T cells in the brain during chronic infection. 
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Discussion 
 STAT3 is an important transcription factor involved in numerous signaling 
cascades from multiple cytokine and it was shown that T. gondii directly phosphorylates 
STAT3 to specifically interfere with macrophage production of IL-12p40 and TNF-α 86, 
87, 270.  These studies implied that macrophages were an important cell type in resistance 
to T. gondii and that BMMφ were indicative of macrophage/monocyte populations that 
the parasite might encounter in vivo. Because STAT3-knockout mice are embryonic 
lethal succumbing early during development 279, the ability to make conditional 
knockouts of STAT3 in macrophages provided a useful tool to determine the role of 
macrophage-specific STAT3 during T. gondii infection. 
 In contrast to other reports that used human fibroblasts 87, T. gondii induced the 
phosphorylation of STAT3 in macrophages independently of genotype.  Moreover, 
macrophages from LysM-cre Stat3fl/fl mice demonstrated no defect in cytokine production 
in vitro.  They were able to respond to Pru infection and produce IL-12p40 similarly to 
control macrophages and also did not produce TNF-α, IL-6, NO, or the chemokines 
CCL3, CCL4, and CCL5 in response to infection with either strain alone.  Surprisingly, 
STAT3-/- macrophages did not produce enhanced TNF-α or IL-12p40 in response to LPS 
stimulation as was hypothesized.  Indeed, when LysM-cre Stat3fl/fl mice were infected, no 
increase in IL-12 was observed acutely or chronically and there was no difference in 
acute parasite burden at the site of infection.  There was also no difference in survival for 
both RH and Pru infections suggesting that macrophages and neutrophils lacking STAT3 
have little difficulty controlling parasite replication.  There was, however, a significant 
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decrease in parasite DNA in the brains of LysM-cre Stat3fl/fl mice although the presence of 
cysts indicates that this was not sterile clearance. It is surprising that despite lower IL-10 
levels, no enhanced cytokine production or T cell activation was observed but these 
effects may imply that IL-10 cannot act on macrophages to inhibit microbicidal function.  
These anti-microbial effects likely occur either in macrophages at the site of 
inflammation and these acute effects might be observed prior to day 10 or in the brain 
microglia that are assist in controlling chronic parasite burden.  Further experimentation 
on STAT3 in microglia would determine if these effects contributed to the observed 
decrease in parasite DNA in that LysM-cre Stat3fl/fl brains. 
While it is not surprising that LysM-cre Stat3fl/fl mice could not resist RH 
infection, it is interesting that STAT3 did not have an effect on inflammation in vivo.with 
the less virulent Pru given much of the previously reported in vitro data 87, 270.  This 
indicates that either STAT3 is relatively unimportant in macrophages during infection 
because the effects of T. gondii on STAT3 are minimal in vivo, or that macrophages 
themselves are not a major source of IL-12.  These data suggest that although STAT3 is 
upregulated in macrophages by both RH and Pru and this is associated with defective 
pro-inflammatory responses, this effect does not translate into a life or death phenotype 
potentially because other cell types such as dendritic cells are more important for 
cytokine production.  It also implies that perhaps CD11c-cre Stat3fl/fl mice may have the 
predicted enhanced resistance because it is a more prominent producer of IL-12 during T. 
gondii infection. This subject will be discussed in more detail in Chapter V. 
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III. 
 
In the absence of SOCS3, IL-6 is a potent inhibitor of 
the immune response. 
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Abstract 
Resistance to Toxoplasma gondii is dependent upon interferon-γ (IFN-γ) signaling 
which induces both pro-inflammatory cytokines and effector molecules that allow 
infected cells to kill this pathogen.  T.gondii has developed multiple mechanisms to evade 
this response including the ability to activate STAT3 in host cells that inhibits pro-
inflammatory responses. Suppressor of Cytokine Signaling molecule 3 (SOCS3) is a 
protein downstream of STAT3 signaling with multiple inhibitory effects including 
limiting IL-6 signaling.  The studies presented here reveal that SOCS3 is upregulated in 
macrophages following infection with T. gondii and when mice that lack SOCS3 in 
macrophage and neutrophil lineages (LysM-cre Socs3fl/fl) were challenged with this 
parasite, they succumbed to infection associated with high parasite burdens.  This 
enhanced susceptibility is not the result of delayed or decreased immune cell recruitment 
but is instead due to impaired production of IL-12 and IFN-γ, leading to an inability to 
restrain parasite replication. This phenomenon is explained by the observation that 
neutralization of IL-6 in LysM-cre Socs3fl/fl mice resulted in improved control of parasite 
load and prolonged survival. Together, these data provide direct in vivo evidence that the 
ability of SOCS3 to suppress IL-6 signals is essential for resistance to T. gondii. 
 
 
 
 
 
 62 
Introduction 
Toxoplasma gondii is an opportunistic pathogen of patients with a variety of 
primary and secondary deficiencies in T cell function 3, 51, 280.  Numerous experimental 
systems have shown that control of T. gondii is achieved through a combination of innate 
and adaptive responses that are dependent upon accessory cell production of IL-12 that 
drive natural killer (NK) and T cells to produce IFN-γ 15, 18, 103, 281, 282. These cytokines are 
critical for long term-resistance to T. gondii as mice deficient in either IL-12 or IFN-γ 
succumb to the acute phase of this infection 15, 18, 103, 281, 282. Secreted IFN-γ stimulates 
antigen-presenting cells, including macrophages, to upregulate effector functions that 
enhance microbial killing. In current models, the ability of IFN-γ to activate the 
transcription factor STAT1 synergizes with factors such as TNF-α, IL-1, and CD40L that 
utilize NFκB signaling to promote robust anti-microbial responses 112, 283.  Together, 
these stimuli induce the expression of numerous genes, such as those that code for 
inducible nitric oxide synthase (iNOS) and the Interferon Responsive Gene (IRG) family 
of p47 GTPases, that are critical for resistance to T. gondii 284-286.  
Similar to many other pathogens, T.gondii has evolved a number of strategies to 
evade host anti-microbial activity.  For example, multiple groups have provided evidence 
that T. gondii can interfere with the activation of NFκB 287-289.  Similarly, T.gondii has 
been shown to antagonize IFN-γ signaling by inhibiting the phosphorylation of STAT1 
and preventing its nuclear translocation and by upregulating SOCS1, a suppressor of 
IFN-γ-signaling 290-292.  This pathogen has also been shown to interfere with recruitment 
of p47 GTPases to the parasitophorous vacuole, thus limiting the ability of IFN-γ-
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activated cells to control parasite replication 284, 285, 293. More recent work has highlighted 
the role of the transcription factor STAT3 in the ability of T. gondii to evade host 
responses 86, 88, 272. Under normal circumstances, STAT3 is activated by a number of 
cytokines including IL-6 and IL-10, which have been linked to direct inhibition of anti-
microbial effector function as well as enhancement of the growth of pathogens such as T. 
gondii, Mycobacterium, and Leishmania species 294-296.  Notably, T.gondii injects a 
rhoptry kinase, ROP16, that directly phosphorylates STAT3 independently of either IL-6 
or IL-10, and this event is associated with impaired IL-12p40 and TNF-α production by 
macrophages 86 87, 285. These observations suggest that the ability of T. gondii to directly 
activate STAT3 limits anti-microbial responses and promotes parasite survival.  
Although STAT3 appears to be a key target of T. gondii during infection, the 
downstream effects of STAT3 that promote parasite replication are unclear.  One 
candidate gene, upregulated by IL-6 and IL-10-mediated activation of STAT3, is 
Suppressor of Cytokine Signaling 3 (SOCS3). SOCS3 binds to the granulocyte colony-
stimulating factor receptor (G-CSFR), the leptin receptor, and also to the gp130 subunit 
of the IL-6 receptor complex where it limits IL-6 signaling but does not appear to 
interfere with IL-10-mediated events 254, 267, 297-299.  In addition, SOCS3 has also been 
proposed to limit NFκB signals and to act as an ubiquitin ligase and represents an ideal 
candidate to mediate components of the suppressive effects of T. gondii invasion 300, 301. 
To investigate if macrophage SOCS3 is involved in the ability of T. gondii to suppress 
the immune response, we utilized mice in which the Socs3 gene is flanked by loxP sites 
and Cre recombinase is inserted under the control of the Lysozyme M promoter to 
specifically delete Socs3 from macrophages and neutrophils (LysM-cre Socs3fl/fl).  
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Although SOCS3 was not required for the ability of T. gondii to suppress cytokine 
production in vitro, infection of these mice resulted in overwhelming parasite burdens 
characterized by impaired neutrophil, monocyte, Natural Killer, and T cell responses and 
these animals succumbed acutely to infection. Administration of neutralizing antibodies 
to IL-6 blocked disease susceptibility suggesting that in the absence of SOCS3, 
macrophages are hypersensitive to the anti-inflammatory properties of IL-6. 
IL-6 is a cytokine with many described pleiotropic effects.  It has historically been 
considered to be pro-inflammatory, having these actions in disease models of arthritis and 
asthma 194, 302.  There is evidence that IL-6 is required for chronic control from T. gondii 
as IL-6-/- mice succumb to chronic infection due to impaired humoral immunity (Silver 
unpublished studies) 180, 303. However, IL-6 has anti-inflammatory properties as in vitro 
activation and killing by macrophages stimulated with IFN-γ and TNF-α was able to be 
impaired in the presence of IL-6 and was true for a number of infectious organisms 
including T. gondii, L. braziliensis, and M. avium 294, 296, 304.  While IL-6 has anti-
microbial responses during T. gondii,  this chapter will address the role that IL-6 plays in 
inhibiting pro-inflammatory responses and discuss how these actions are exacerbated in 
the absence of its negative regulator, SOCS3. 
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Materials and Methods 
Mice and infections 
LysM-cre Socs3fl/fl mice were originally generated by Douglas Hilton and Warren 
Alexander as previously described 305.  C57/Bl6 mice were obtained from Taconic Farms 
Inc (Germantown, NY). C57/Bl6, Socs3fl/fl, and LysM-cre Socs3fl/fl mice were bred in the 
University Laboratory Animal Resources facilities at the University of Pennsylvania. All 
procedures were performed in accordance to the guidelines of the University of 
Pennsylvania Institutional Animal Care and Use Committee.  RH and Prugniaud (Pru) 
parasites were grown in Human Foreskin Fibroblast (HFF) monolayers cultured with D10 
media (DMEM, 25% M199 Supplement, 10% Fetal Bovine Serum, 0.5% 
penicillin/streptomycin (10,000 µg/mL), 0.5% gentamycin (50 µg/mL)) and harvested as 
previously described 273. Tomato-expressing RH and Pru parasites were grown and 
harvested as previously described 275.  Bone-marrow derived macrophages (BMMφ) were 
flushed from mouse femurs and grown for 6 days in DMEM containing 1% sodium 
pyruvate, 1% penicillin/streptomycin, 10% FBS, 30% L929 cell supernatant, and 1% 
HEPES 269, 273.  All Pru infections were performed i.p. with 104 parasites except for Pru-
Tomato where 106 was used.   Infection with Me49 was performed with 20 cysts i.p.  
Injections of 200 µg of α-IL-6 (BioXCell, West Lebanon, NH) or rat IgG (Sigma, St. 
Louis, MO) were administered i.p. at day -1 and 2 post-infection.  For vaccination 
studies, 5 mice per group were given 106 CPSII parasites intraperitoneally for 7 days 
followed by challenge with 104 Pru. Thioglycollate injections were performed i.p. with 
0.5 mLs of 4% Brewer’s thioglycollate medium (Sigma) and peritoneal exudates cells 
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(PECs) were harvested on day 4 as described 273.  2.5x105 thioglycollate-elicited 
macrophages were then plated for 24 hrs in 200 µl total volume and supernatants were 
used for detection of IL-12p40 production by ELISA. 
 
Immunoblotting 
106 BMMφ were cultured in 96 well plates overnight and then infected with 5:1 Pru 
parasites for the indicated durations.  Lysates were prepared using TNT buffer (0.1 M 
Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20) combined with complete protease 
inhibitors (Roche, Mannheim, Germany) at 1:100 for 20 minutes on ice and then stored at 
-20°C.  Samples were electrophoresed and transferred to Immobulon-P membrane 
(Millipore, Bedford, MA) and blocked for 1 hr in 5% nonfat dry milk and probed 
overnight with mouse monoclonal antibodies to SOCS3 (Invitrogen, Carlsbad, CA), β-
actin, pSTAT3, total STAT3, pSTAT1, total STAT1, pERK, and total ERK (Cell 
Signaling, Danvers, MA).  Blots were washed in TBS-Tween 3 times and probed with α-
mouse or α-rabbit secondary antibodies conjugated to horseradish peroxidase (Jackson 
ImmunoResearch, West Grove, PA) at 1:10,000 for 1 hr at room temperature.  Blots were 
washed 3 times and developed with enhanced chemiluminescence and exposed to film.  
Results are representative of two independent experiments. 
 
Confocal immunofluorescence microscopy 
5x105 BMMφ were isolated and cultured in 96 well plates and infected at a multiplicity of 
infection (MOI) of 1:1 Pru parasites.  Cells were blocked, fixed with 2% 
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paraformaldehyde, incubated with monoclonal α-SOCS3 (Invitrogen) overnight, washed, 
and detected by incubation with biotinylated anti-mouse antibodies and streptavidin 
conjugated to Alexafluor 488 (Invitrogen) for an additional hr.  Cells were then washed, 
centrifuged onto slides, and visualized using the Nikon Eclipse E600 microscope 
(Melville, NY) equipped with a Photometrics Cool Snap EZ CCD camera (Tucson, AZ). 
Results are representative of two independent experiments.  Transwell experiments were 
performed with a 0.5mM filter.  106 BMMφ were plated onto 12 well plates containing 
coverslips.  Adjacent wells with cells but without coverslips were infected with parasites 
(1:1 M.O.I.) for 60 minutes, loosened with a cell scraper, then transferred to the top of the 
transwells over wells with no parasites for 3hrs.  After 3 hrs, the transwell was removed 
and the coverslips with fixed and stained as described above for other immunofluorescent 
studies.  Supernatants from these infected cells were taken and layered onto other naïve 
cells for 3 hrs to serve as an additional control.  These results are not shown but discussed 
in the text. 
 
RNA isolation and quantitative Real Time PCR 
RNA was isolated using the RNeasy kit (Qiagen) according to manufacturer’s 
instructions and reverse transcribed into cDNA using Superscript II (Invitrogen) using 
standard protocols. Quantitative PCR was performed with customized primer sets for 
Socs3 (Forward 5’-ACCAGCGCCACTTCTTCACG-3’, Reverse 5’-
GTGGAGCATCATACTGATCC-3’) and Socs1 (Forward 5’-
ACTTCTGGCTGGAGACCTCA-3’, Reverse 5’-CCCAGACACAAGCTGCTACA-3’) 
using Power SYBR green reagents and an AB7500 Fast Real Time PCR thermal cycler 
(Applied Biosystems, Warrington UK). The values for Socs3 were normalized to β−Actin 
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(Qiagen, Germantown, MD).  The arg1 primer set was purchased from Qiagen. Parasite 
DNA levels were measured by real time PCR on DNA isolated from the tissue samples 
using the High Pure PCR Template Purification Kit (Roche). For measurement of 
parasite burden, the 35-fold repetitive T. gondii B1 gene was amplified by real-time PCR 
with SYBR Green PCR Master mix (Applied Biosystems) in an AB7500 fast real-time 
PCR machine (Applied Biosystems) using published conditions 25.  These experiments 
were repeated twice with similar results. 
 
Cytokine and flow cytometric analysis 
Whole splenocytes were washed and resuspended in complete RPMI 1640 (Invitrogen) 
containing 10% FBS (Serum Source International), 1% penicillin/streptomycin 
(Invitrogen), 1 mM sodium pyruvate (Mediatech, Manassas, VA), 2 mM L-glutamine 
(Mediatech), 0.1% 2-mercaptoethanol (Invitrogen) before being plated at a cell density of 
106 cells per well in a final volume of 200 µl in 96-well plates (Costar, New York). Cells 
were stimulated with or without soluble Toxoplasma antigen (STAg) at 50 µg/mL, or α-
CD3 at 1µg/mL (eBioscience) for 24 hr at 37 C in 5% CO2. Peritoneal cells were isolated 
as previously described 25 and cell-free peritoneal wash fluid was used for cytokine 
analysis. Concentrations were normalized to the amount of peritoneal fluid recovered 
from each mouse. Blood was collected via cardiac puncture.  Concentrations of IFN-γ, 
IL-12p40, and IL-6 were determined by ELISA using antibodies from eBioscience (San 
Diego, CA).  Freshly isolated PECs from infected mice were incubated with Fc block 
(0.1 µg/mL 24G2 antibody) for 15 min prior to surface staining with Ly6C-PerCP 5.5 
(HK1.4), CD11b-FITC (M1/70), F4/80-eFluor 780 (BM8), GR1-PECy7 (RB6-8C5), 
 69 
CD86-APC (16-10A1), CD80-PE (GL1), NK1.1-PE (PK136), CD4- eFluor. 780 (RM4-
5), CD8-PerCP 5.5 (53-6.7), CD19-PECy7 (eBio1D3 (1D3)), CD11c-APC (N418), 
CD62L-APC (MEL-14), and CD44-PE (IM7) (eBioscience, San Diego, CA), MHC Class 
II I-A/I-E (Biolegend, M5/114.15.2), CD3ε-Pacific Blue (500A2), and CD19-Pacific 
Blue (1D3) (BD Biosciences). For intracellular cytokine staining, 106 PECs were plated 
in RPMI 1640 and stimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) in the 
presence of brefeldin A (10 µg/mL) (Sigma) for 4 hrs at 37 °C with 5% CO2 unless 
otherwise noted. The cells were fixed with 2% paraformaldehyde following surface stain. 
(Electron Microscopy Science, Hatfield, PA) for 10 min. For intracellular staining, the 
cells were permeabilized with 0.5% saponin (Sigma, St. Louis, MO) and stained with 
anti-IFN-γ-APC (XMG1.2) or IL-12p40-APC (17.8) (eBioscience). All flow cytometry 
was performed on a FACSCanto using FACSDIVA 6.0 software (BD Biosciences, San 
Jose, CA). Analysis was performed using FlowJo software (Treestar Inc., Ashland, OR). 
 
In vitro killing assay and inhibition assays 
5x105 BMMφ were harvested and cultured in 96 well plates and pretreated overnight with 
media alone or IFN-γ  (BD Biosciences, San Jose, CA) and TNF-α (eBioscience) at 
indicated concentrations. Cells were then infected with Pru at 1:1 and incubated 
overnight.  Cells were then centrifuged onto microscope slides and the number of 
infected macrophages was counted.  Nitrite analysis was performed using the Griess 
protocol.  Briefly, 50µl of sample was added to equal volume of a mixture (1:1) of 1% 
sulfanilamide and 0.1% naphthylethylenediamine in 2% (vol/vol) phosphoric acid. After 
incubation at room temperature, the optical density of the reaction product was measured 
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at a wavelength of 540 nm and the nitrite concentration was calculated with sodium 
nitrite as a standard.  For parasite cytokine-inhibition assays, 2x105 BMMφ were plated 
and infected with either RH or Pru parasites at an MOI of 1:1 for 1 hr prior to LPS 
stimulation (100 ng/mL, Sigma) for 24 hours.  For IL-6 inhibition assays, BMMφ were 
stimulated with IFN-γ (10ng/mL) and LPS (10ng/mL) with or without IL-6 (10 ng/mL) at 
10 fold increments beginning at 0.001 ng/mL (eBioscience) or α-IL-6 (100 ng/mL, 
BioXcell).  ELISAs of supernatants from 24 hr cultures were performed using antibodies 
for IL-12p40, IL-6, IL-10, and TNF-α (eBioscience).  CCL3, CCL4, and CCL5 ELISAs 
were performed with DuoSet kits provided by R&D Systems (Minneapolis, MN). 
 
Arginase activity 
Arginase activity was performed as described 306. Briefly, 106 BMMφ were plated in 
sterile microcentrifuge tubes and stimulated with 40 ng/mL IL-4 (Peprotech, Rocky Hill, 
NJ), 10ng/mL IL-10, or infected with RH or Pru (M.O.I. 5:1) for 1 hr.  Cells were washed 
in PBS and were lysed with 100 µl Triton 100X, and given 50µl of 10 mM MnC12,and 
50 mM Tris-HCl, pH 7.5 were added and the enzyme was then activated for 10 minutes 
at 55°C.  Arginine hydrolysis was performed by adding of 25µL of 0.5 M arginine, pH 
9.7 to a 50 µl aliquot of the previously activated lysate. Incubation was per-formed at 
37°C for 60 min and the reaction stopped by the addition of 400 µl of an acid mixture 
containing H2SO4, H3PO4 and H2O (1:3:7).  Urea output was measured the urea 
colorimetrically 540 nm. 
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Statistical analysis 
Statistical analysis was conducted on normally distributed data with Students’ t test or 
One-Way ANOVA, and calculated with Prism software (Graphpad Software).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
Results 
Toxoplasma gondii upregulates SOCS3 in macrophages. 
Previous studies have shown that infection of macrophages with T. gondii in vitro 
results in the rapid phosphorylation of STAT3 through a mechanism independent of IL-6 
or IL-10 87, 88.  Since STAT3 activation is associated with the induction of SOCS3, 
experiments were performed to determine if T. gondii infection also led to the 
upregulation of SOCS3. Therefore, SOCS3 mRNA and protein were measured in bone 
marrow-derived macrophages (BMMφ) (A) and resident peritoneal macrophages (B) 
infected with the Type I strain (RH) or a Type II strain (Prugniaud) of T. gondii.  
Unstimulated cells had a low basal level of SOCS3 mRNA with no observable SOCS3 
protein, while infection with either strain of T. gondii induced a rapid increase in SOCS3 
mRNA (Figure 9A,B). SOCS3 mRNA was upregulated following 1 hr of infection and 
remained elevated at 3 hrs, an effect that was comparable to that observed following 
stimulation with IL-6 (Figure 9B, black bars). SOCS3 protein was also found to be 
upregulated following infection with live infection only as macrophages treated with 
STAg did not upregulate SOCS3 protein (Figure 9C).  
To directly assess if infected cells expressed SOCS3, immunofluorescence was 
performed on BMMφ infected for 3 hrs with a transgenic RH parasite that expresses the 
fluorescent protein Tomato (RH-Tomato). To confirm specificity, macrophages deficient 
in SOCS3 were used and SOCS3 protein was not detected by immunofluorescence in 
resting macrophages or those lacking SOCS3 isolated from LysM-cre Socs3fl/fl mice 
(Figure 9E).   Additionally, SOCS3 mRNA was not observed in SOCS3-deficient 
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macrophages infected with either strain of parasite (Figure 9B, white bars).  SOCS3 
deletions were specific for SOCS3 as T. gondii was still able to induce upregulation of 
SOCS1 in peritoneal macrophages (Figure 9D).  Additionally, following infection there 
was increased SOCS3 expression in wild type cells while fluorescence was absent in 
knockout cells (Figure 9E).   
The images in Figure 9E revealed that in wild type macrophages, SOCS3 was 
upregulated in both infected and uninfected cells. Based on a recent report that T. gondii 
can inject rhoptry proteins that influence host cell signaling without directly infecting 
them studies were performed to assess whether this phenomena contributed to the 
expression of SOCS3 in uninfected cells 307, 308. Therefore, transgenic parasites that 
expressed Cre recombinase (Pru-Cre-Cherry and RH-Cre-Cherry) were used to infect 
Socs3fl/fl BMMφ for 3 hrs and compared to control parasites containing empty vectors 
Pru-PCL1-Cherry and RH-Tomato respectively (Figure 10A,B). If rhoptry proteins are 
involved in the upregulation of SOCS3, then the injection of the Cre recombinase should 
excise the Socs3 gene and the infection-induced upregulation of SOCS3 typically 
observed in these cultures should be reduced.  It should be noted here that these effects 
were not observed when cells were infected for shorter time points such as 1hr indicating 
that there is a lag between the infection and the time required to excise the gene.  In 
Figure 10A, there is no upregulation of SOCS3 in uninfected cells but a dramatic increase 
in SOCS3 expression following infection with the Pru strain expressing an empty vector, 
Pru-PCL1-Cherry.  However, Pru-Cre-Cherry induced no upregulation of SOCS3 in 
either infected or uninfected cells and the brightfield view is shown here to verify 
infected cells (Figure 10A). This was also observed in RH-Cre-Cherry-infected cultures 
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where no upregulation of SOCS3 was observed (Figure 10B).  Additionally, while the 
RH-Tomato parasites induced SOCS3 expression in uninfected and infected cells, this 
was markedly reduced (by approximately 10 fold, 55% versus 5%) when the RH-Cre-
Cherry parasites were used (Figure 10B,C). When supernatants from macrophages 
infected with T. gondii were directly added to cultures of uninfected cells this did not lead 
to the upregulation of SOCS3 (data not shown) and when infected cells were placed on 
the top of a Transwell apparatus, there was no upregulation of SOCS3 in the lower cell 
layer (Figure 10A, bottom panels).  Together, these data are consistent with a model in 
which the ability of the parasite to inject rhoptry proteins into infected and uninfected 
cells explains the widespread expression of SOCS3 that we observed.  
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Figure 9.  T. gondii upregulates SOCS3 in macrophages. 
Cultures of macrophages infected with T. gondii demonstrate increases in SOCS3 mRNA 
and protein that is correlated with STAT3 phosphorylation and decreased IL-12p40 
secretion.  SOCS3-deficient macrophages show stronger STAT3 phosphorylation and a 
defect in IL-12 production. A,B) 106 BMMφ (A) or resident peritoneal macrophages (B) 
from C57/Bl6 mice were infected with RH or Pru at an M.O.I. of 5:1 for the 3 hrs.  
Peritoneal macrophages were also stimulated with IL-6 (100 ng/mL) for 3 hrs.  RNA was 
extracted, reverse transcribed into cDNA and Quantitative Real Time PCR was 
performed using SOCS3-specific primers.  Results are relative to β-Actin and 
representative of two experiments. C) Western blot analysis was performed on lysates of 
106 BMMφ infected at 1:1 with RH, Pru, or stimulated with STAg (50 µg/mL) and the 
lysates were probed with a SOCS3-specific antibody and compared to β-Actin.  D) 
Quantitative Real Time PCR was performed with primers specific to SOCS1 and SOCS3 
and normalized to β-Actin for SOCS3 and SOCS1 from resident peritoneal macrophages 
isolated from naïve control mice, Socs3fl/fl, or LysM-cre Socs3fl/fl mice and incubated with 
RH, Pru, or IL-6 (100ng/mL) for 3 hrs. E) BMMφ were infected at 1:1 for 1 hr with RH-
Tomato and then fixed, stained with DAPI and antibodies to SOCS3 conjugated to 
Alexafluor 488, and transferred to slides for confocal microscopy.  
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Figure 10. Upregulation of SOCS3 by T. gondii requires direct invasion or injection 
of parasite proteins. 
When macrophages are cultured with either RH or Pru parasites, they upregulate SOCS3 
and this is dependent upon injection of parasite proteins presumably secreted rhoptry 
proteins. To address this, 5x105 Socs3fl/fl BMMφ that do not express Cre were plated on 
coverslips and infected for 3 hours with fluorescent Pru parasites that expressed either cre 
recombinase or a control protein or media alone.  A) Media alone did not induce 
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upregulation while Pru that expressed the control protein (Pru-PC1L-mCherry) strongly 
induced the upregulation of SOCS3 (Top, 1st two panels).  Incubation with Pru-Cre-
mCherry failed to induce the upregulation of SOCS3 in infected or uninfected bystander 
cells suggesting that direct infection of the parasite is required for SOCS3 expression.  
Transwell experiments were also performed to support this as 5x105 Socs3fl/fl BMMφ on 
coverslips on the bottom of the 24 well plates while cells infected for 1 hour were added 
to the top of the Transwell for 3 hours.  Neither strain of Pru parasite was able to induce 
upregulation of SOCS3 in cells that did not directly contact the parasite (A, bottom 2 
panels).  B)  Similar to A), RH-Tomato or RH-Tomato expressing Cre recombinase was 
used to infect Socs3fl/fl BMMφ for 3 hours.  When the parasite expresses Cre it is unable 
to upregulate SOCS3 in neighboring cells demonstrating that direct infection is required.  
This is quantified in (C) where the total percentage of SOCS3+ cells is shown.  In cells 
infected with the control strain of RH, a high percentage of cells are positive for SOCS3 
and nearly 3 times as many were currently infected at the time of fixation (C, both 
panels).  For RH-Tomato-Cre parasites, very few cells are positive for SOCS3 and very 
few of these are currently infected suggesting that this low level of SOCS3 is background 
upregulation. These data are indicative of two independent experiments and confirm that 
direct infection of the cell is required for SOCS3 upregulation. 
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LysM-cre Socs3fl/fl macrophages have exaggerated pSTAT3 signaling following infection 
and produce less IL-12 when stimulated. 
Since it has been shown that the ability of T. gondii to antagonize IL-12p40 and 
TNF-α production from LPS-stimulated macrophages is STAT3-dependent, experiments 
were performed to determine if this effect was also SOCS3-dependent 270. Infection of 
wild type BMMφ resulted in a rapid phosphorylation of STAT3 that starts to decline by 4 
hrs and is nearly absent by 24 hrs in SOCS3-sufficient macrophages infected with either 
RH or Pru (Figure 11A,B).  In SOCS3-deficient macrophages, the infection-induced 
phosphorylation of STAT3 is detected at 1 and 4 hrs post infection but remained elevated 
for up to 24 hrs.   This result was consistent with studies demonstrating IL-6 to have 
stronger effects in the absence of SOCS3 252, and suggests that the mechanism utilized by 
SOCS3 to limit IL-6-activated STAT3 may also affect STAT3 phosphorylation by T. 
gondii (Figure 11A,B). To assess whether the presence of SOCS3 was required for the 
ability of T. gondii to limit IL-12p40 production, control or SOCS3-deficient 
BMMφ were infected for 1 hr prior to LPS stimulation, and then incubated for 24 hrs 
before cytokine analysis.  Stimulation of wild type macrophages with LPS resulted in IL-
12p40 secretion and this was reduced when SOCS3-deficient macrophages were used 
(p<0.01) (Figure 11C). Infection with RH or Pru resulted in a significantly reduced 
ability of LPS to induce IL-12p40 in wild type and SOCS3-deficient macrophages 
(Figure 11C).   Together, these findings suggest that infection leads to an upregulation of 
SOCS3, but this protein is not required for the ability of T. gondii to impair cytokine 
secretion by macrophages. 
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Figure 11. LysM-cre Socs3fl/fl macrophages have enhanced pSTAT3 signaling and 
decreased pro-inflammatory responses following infection with T. gondii. 
SOCS3 is upregulated following infection with T. gondii.  In order to determine if 
SOCS3 is necessary for STAT3-mediated inhibition of pro-inflammatory responses, 
western blot analysis was performed on lysates of 106 BMMφ infected at 1:1 with RH or 
Pru for the indicated time points. A) Lysates were probed with pSTAT3 and total STAT3 
and compared to β-Actin. These data suggest that in the absence of SOCS3, T. gondii 
induces enhanced pSTAT3 signaling.  To investigate whether the parasite can still inhibit 
pro-inflammatory responses in the absence of SOCS3, 2.5x105 BMMφ were infected for 
1 hr prior to stimulation with LPS.  C) Supernatants were measured following 24 hrs of 
stimulation for IL-12p40.  These data indicate that SOCS3 is not required for STAT3-
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mediated inhibition of pro-inflammatory cytokines.  Experiments were performed twice 
with similar results.  Mean +/- SD. Western blots were performed by Carolyn M. Gray. 
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LysM-cre Socs3fl/fl mice succumb acutely to T.gondii infection with high 
parasite burdens. 
To assess the possible role of SOCS3 in the response to T. gondii, LysM-cre 
Socs3fl/fl and Socs3fl/fl littermate control mice were infected with Pru and the disease 
course was monitored.  While Socs3fl/fl mice survived infection, LysM-cre Socs3fl/fl mice 
were highly susceptible to the acute phase of infection, succumbing by day 10 (Figure 
12A). To evaluate parasite replication in these mice, the number of infected cells in the 
peritoneal cavity was counted. In Socs3fl/fl control mice, there were few infected cells in 
the peritoneal cavity at day 4 with little increase by day 8 (Figure 12B,C).  A similar 
number of infected cells were observed in the peritoneal cavity of LysM-cre Socs3fl/fl at 
day 4 as compared to Socs3fl/fl mice; however, there was a significant increase in parasite 
burden by day 8 in the peritoneal cavity of LysM-cre Socs3fl/fl including the presence of 
free tachyzoites (bottom right arrow) (Figure 12C).  Additionally, following infection 
with Pru-Tomato, there was a significantly elevated percentage of Tomato+ infected cells 
in the peritoneal cavity in LysM-cre Socs3fl/fl mice that did not vary by cell type (Figure 
12D,E).  As determined by real-time PCR, there was detectable parasite DNA in the 
livers of all mice that was statistically higher in LysM-cre Socs3fl/fl mice than Socs3fl/fl at 
day 4 and increased dramatically at day 8 (Figure 12F). Histopathological analysis of 
liver and lung sections identified little inflammation in control mice yet showed increased 
areas of necrosis (arrows) in the liver and enhanced inflammation in the lung of LysM-cre 
Socs3fl/fl mice (Figure 12G).  These results suggest that enhanced parasite replication led 
to the observed tissue damage. 
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Figure 12. LysM-cre Socs3fl/fl mice succumb acutely to T. gondii infection. 
Infection of LysM-cre Socs3fl/fl mice leads to acute mortality associated with increased 
parasite burden in the peritoneal cavity and liver along with increase pathology in the 
liver and lungs.  A) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were infected i.p. with 
104 Pru parasites and survival was monitored. Infected mice were also sacrificed on day 8 
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to determine parasite burden.  B,C) PECs were collected, centrifuged onto slides, and 
visualized using light microscopy for the percentage of infected cells.  Arrows denote 
both intracellular and extracellular tachyzoites although only cells with intracellular 
parasites were considered infected. D,E) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were 
infected i.p. with 106 Pru-Tomato parasites and PECs were isolated at day 4 post-
infection.  The total number of live, Pru-Tomato+ cells was counted using flow cytometry 
gated on Tomato+ events from the PE channel. E) From the Pru-Tomato+ cells, the 
percentage of positive cells that were monocytes (CD11b+, F4/80+, Ly6C+), neutrophils 
(CD11b+, F4/80-, Ly6Clow, GR1+), T cells (CD3+ and CD4+ or CD8+), and NK cells 
(CD3+, NK1.1+) were evaluated and depicted. F) DNA was extracted from spleen and 
liver tissue from day 8 infected mice (n=5) and analyzed by Real Time PCR for parasite 
DNA.  G) Livers and lungs of infected (day 8) mice were fixed, sectioned, and imaged 
using confocal microscopy.  Arrows denote regions of increased pathology. Images and 
results are representative of two independent experiments. Statistical values were 
determined by Student’s t tests. Experiments were performed twice with similar results. 
Mean +/- SD. 
 
 
 
 
 
 
 
 86 
Inflammatory monocytes and neutrophils are activated and recruited to the 
site of inflammation. 
Several studies have established that inflammatory monocytes and neutrophils are 
required for acute resistance to T. gondii 108-110, 309.  Phenotypically, inflammatory 
monocytes are CD11b+, F480+, Ly6Chi, CD62L+, MHCIIhi, and CCR2+, and are thought 
to migrate to primary sites of infection and contribute to the control of T. gondii 109, 309.  
To test if the enhanced susceptibility of LysM-cre Socs3fl/fl mice was due to altered 
recruitment of these populations, flow cytometric analysis was performed on isolated 
peritoneal cells from mice infected for 4 days. While the overall number of peritoneal 
cells was similar between Socs3fl/fl control and LysM-cre Socs3fl/fl mice at day 4, there 
was a statistically significant increase in recruited cells in LysM-cre Socs3fl/fl mice at day 
8 (p<0.05) (Figure 13A). Evaluation of CD3- CD11b+ cells in the peritoneal cavity of 
uninfected mice revealed that the majority of these cells possessed a phenotype (F4/80hi, 
Ly6Cneg) associated with resident macrophages (Figure 13B, left panel). Also, there was 
no difference in the number of resident peritoneal macrophages between control and 
LysM-cre Socs3fl/fl mice (data not shown).  Upon infection, there was recruitment of 
neutrophil (CD11b+, Ly6Clow, F4/80low, GR1hi) and inflammatory monocyte populations 
(CD11b+, F4/80hi, Ly6Chi, Figure 13B top right quadrant) to the peritoneal cavity by day 
4, but no significant difference in number was observed between Socs3fl/fl and LysM-cre 
Socs3fl/fl mice (Figure 13C). Moreover, no significant difference in surface expression of 
CD62L, MHCII, CD80, and CD86 was observed between neutrophils or inflammatory 
monocytes from LysM-cre Socs3fl/fl and control mice suggesting that these populations 
express appropriate levels of surface activation markers (Figure 13D-G).  To assess their 
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functionality, the ability of inflammatory monocytes and neutrophils to produce IL-12p40 
during infection was measured.  Critically, there was a significant reduction in the 
percentage of IL-12p40+ inflammatory monocyte and neutrophils from LysM-cre Socs3fl/fl 
mice at day 4 post-infection (Figure 13H,I). Together, these findings indicate that the 
inability of LysM-cre Socs3fl/fl mice to control parasite replication is not a consequence of 
a failure to recruit activated neutrophil or inflammatory monocyte populations, but may 
in fact be due to the reduced ability of these cells to produce IL-12. 
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Figure 13. Inflammatory monocytes and neutrophils from LysM-cre Socs3fl/fl mice 
are deficient in IL-12 production following infection. 
LysM-cre Socs3fl/fl mice show impaired IL-12 production from neutrophil and 
inflammatory monocyte populations recruited to the peritoneal cavity following infection.  
A) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl  (n=5) were infected i.p. with 104 Pru parasites 
and sacrificed at days 4 and 8 post infection and the total number of cells in the peritoneal 
cavity was quantified.  B,C) Live, singlet, CD19-, CD3-, CD11b+ cells were analyzed for 
the surface markers Ly6C and F4/80 to identify inflammatory monocytes 
(F4/80hi,Ly6Chi) and neutrophils (F4/80low,GR1+, Ly6Clow) and quantified. D-G) 
Monocyte and neutrophil populations were stained for the surface markers of activation 
MHC Class II, CD62L, CD80, and CD86 and compared for the overall expression by 
MFI. H,I) To determine IL-12 production from these cell types, intracellular cytokine 
staining was performed by incubating 106 PECs with BFA and Golgi Stop for 5 hrs, 
staining with surface markers for monocytes and neutrophils, fixing with 
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paraformaldehyde, staining for intracellular IL-12p40, and analyzing by flow cytometry. 
Mean Fluorescence Intensity was calculated and is depicted in red. I) The percentage of 
IL-12p40+ inflammatory monocytes and neutrophils are shown.  One-Way ANOVA 
followed by student’s t test was used to determine statistical significance.  Results are 
representative of two independent experiments. Mean +/- SD. 
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LysM-cre Socs3fl/fl mice have impaired NK and T cell responses. 
Since IL-12 is critical for NK and T cell–mediated resistance to T. gondii, these 
populations were examined to determine if the loss of SOCS3 in macrophages and 
neutrophils affected their ability to produce IFN-γ.  At day 4, similar numbers of CD4+, 
CD8+, and NK1.1+ cells were observed in Socs3fl/fl control and LysM-cre Socs3fl/fl mice 
suggesting that the loss of SOCS3 in macrophages and neutrophils did not impair 
recruitment of these populations to the site of infection (Figure 14A).  Although there 
was no observed difference in the population of naïve CD4+ T cells in LysM-cre Socs3fl/fl 
mice, there was a statistically significant decrease in activated CD62Llow, CD44hi CD4+ T 
cells (Figure 14B,C).  Furthermore, CD4+ T and NK cells from LysM-cre Socs3fl/fl mice 
were significantly impaired in their ability to produce IFN-γ at day 4 as compared to 
control mice with CD8+ T cells demonstrating the same trend though not statistically 
significant (Figure 14D,E). To further evaluate the ability of LysM-cre Socs3fl/fl T cells to 
produce IFN-γ, splenic recall assays were performed.  Surprisingly, after 24 hrs of 
incubation with media alone, αCD3, or STAg, Socs3fl/fl control and LysM-cre Socs3fl/fl 
splenocytes from day 4 infected mice produced comparable IL-12p40 and IFN-γ (Figure 
14F,G). However, impaired production of secreted IL-12p40 was observed in the 
peritoneal lavage fluid at day 4 and a similar trend was observed in the sera (Figure 
15A,B).  Similar production of IFN-γ protein was observed at days 4 and 8 post-infection 
in the serum and peritoneal lavage fluid, suggesting that any defect in the production of 
IL-12 by monocytes and neutrophils may only affect the early production of IFN-γ.  IL-
10 concentrations were similar at days 4 and 8 post-infection in the peritoneum 
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suggesting that the decreased IL-12 levels are not due to increased IL-10 production 
(Figure 15C). Taken together, these findings demonstrate that the reduced ability of the 
LysM-cre Socs3fl/fl mice to control growth of T. gondii is associated with an early defect 
in the ability to produce sufficient IL-12 at the site of infection. 
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Figure 14.  LysM-cre Socs3fl/fl mice recruit T and NK cell populations with impaired 
IFN-γ-producing capabilities. 
 T and NK cells traffic to the peritoneal cavity in appropriate numbers by day 4 following 
infection of LysM-cre Socs3fl/fl mice yet exhibit a less activated phenotype with decreased 
IFN-γ production.  Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl  (n=5) were infected i.p. with 104 
Pru parasites and sacrificed at days 4 and 8 post-infection. A) The total number of NK 
(B220-, CD3-, NK1.1+), CD4+ (B220-, CD3+, CD4+), and CD8+ (B220-, CD3+, CD8+) T 
cells were determined by flow cytometry. A,B) CD4+ T cells were measured for the 
surface markers CD62L and CD44 and (C) quantified for the number of activated 
(CD44hi, CD62Llow) and naïve (CD44low, CD62Lhi) cells per mouse. D,E) For 
intracellular cytokine staining, PECs were incubated with BFA, Golgi Stop, PMA and 
ionomycin for 3 hrs and analyzed for IFN-γ production following surface staining for NK 
cells, and CD4+ and CD8+ T cells. F,G) 106 splenocytes were plated from extracted 
spleens of infected mice and stimulated with media alone or 50 µg/mL STAg.  Levels of 
IL-12p40 and IFN-γ were measured by ELISA following 24 hrs of stimulation.  One-
Way ANOVA followed by student’s t test was used to determine statistical significance.  
Results are representative of two independent experiments. Mean +/- SD. 
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Figure 15. Infected LysM-cre Socs3fl/fl mice show impaired IL-12 production in the 
peritoneal cavity at day 4 post-infection. 
Peritoneal lavage fluid from infected LysM-cre Socs3fl/fl mice contains a lower 
concentration of IL-12p40 at day 4 that corresponds to a similar trend in sera obtained 
from blood.  Although IFN-γ production appears normal at day 4, a diminished IFN-γ 
response was observed at day 8 in the peritoneal lavage fluid. A,B) Fluid from 
intraperitoneal lavage of PECs and serum of infected mice at days 4 and 8 were collected 
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and analyzed by ELISA for IL-12p40 and IFN-γ.  PEC fluid results are present as 
ng/peritoneum which is calculated by multiplying the ELISA concentration (ng/mL) by 
the mL quantity of peritoneal lavage fluid (PBS) recovered following centrifugation. C.) 
PEC fluid concentrations for IL-10 for the indicated time points. One-Way ANOVA 
followed by student’s t test was used to determine statistical significance.  Results are 
representative of two independent experiments. Mean +/- SD. 
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IL-6 blocks IL-12p40 production from macrophages. 
 One possible explanation for the increased susceptibility of LysM-cre Socs3fl/fl 
mice was that SOCS3-deficient macrophages were unable to respond to IFN-γ to control 
T. gondii.  To test whether SOCS3-deficient macrophages could respond appropriately to 
IFN-γ in vitro, BMMφ from Socs3fl/fl and LysM-cre Socs3fl/fl mice were incubated with 
TNF-α and IFN-γ overnight and then infected with Pru for 24 hrs. Stimulated Socs3fl/fl 
control and LysM-cre Socs3fl/fl macrophages limited parasite replication in a 
concentration-dependent manner (Figure 16A,B). To determine if IFN-γ signaling was 
impaired in SOCS3-deficient macrophages, cells were incubated with IFN-γ and the 
phosphorylation of STAT1 and STAT3 was measured. Unlike control macrophages, 
SOCS3-deficient macrophages had abbreviated responses to IFN-γ showing less 
phosphorylated STAT1 at later time points (Figure 16C).  Additionally, control 
macrophages showed an increase in total STAT1 at 20 hrs that was less pronounced in 
SOCS3-deficient cells. This observation did not correlate with a reduced ability of the 
LysM-cre Socs3fl/fl macrophages to produce nitric oxide (NO), suggesting that this altered 
STAT1 signaling pattern did not affect microbicidal activity (Figure 16D). Furthermore, 
IRGs are critical to resistance to T. gondii and when their expression was measured in 
wild type and SOCS3 knockout BMMφ stimulated with IFN−γ, similar levels of Irgm3, 
Irgm1, and Irga6 were detected (Figure 16E).  Moreover, peritoneal cells from day 4 
infected mice show high levels of Irgm3.  They also stain with 3 distinct patterns; small 
cells with dense Irgm3 staining that could be neutrophils, large cells with moderate sparse 
staining that may be macrophages/monocytes, and small cells with no staining that may 
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be T cells (Figure 16F). These populations do not appear different between control and 
LysM-cre Socs3fl/fl mice, which along with the immunoblot staining suggest that deletion 
of SOCS3 appears to have little impact on the ability of IFN-γ to activate anti-microbial 
responses. 
IL-6 has been implicated in inhibiting microbicidal killing from activated 
macrophages.  To test if IL-6 differentially affected LysM-cre Socs3fl/fl macrophages, IL-6 
was added to cultures of macrophages stimulated with IFN-γ and LPS.  Addition of IL-6 
resulted in more infected cells following 24hrs of incubation in wild type and showed a 
similar trend in LysM-cre Socs3fl/fl macrophages although not significant (Figure 17A).  
These results suggested that IL-6 did not preferentially inhibit microbicidal activity in 
LysM-cre Socs3fl/fl macrophages although it could have other consequences of 
exaggerated signaling.  It was previously reported that deletion of SOCS3 from 
macrophages converted IL-6 signals into anti-inflammatory IL-10-like signals due to 
enhanced STAT3 activation 252, 310.  Indeed, IL-6 induced sustained phosphorylation of 
STAT1 and STAT3 in LysM-cre Socs3fl/fl macrophages as compared to Socs3fl/fl 
macrophages, yet demonstrated similar kinetics of activation of the MAP kinase ERK 
suggesting that only STAT signaling is altered in these macrophages (Figure 17B,C) 311.  
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Figure 16. The effects of SOCS3 on IFN-γ  signaling in LysM-cre Socs3fl/fl 
macrophages do not affect microbicidal function.  SOCS3-defiicent macrophages do 
not display impaired microbicidal activity, nitrite production, or IRG expression despite 
altered IFN-γ-mediated phosphorylation of STAT1. A,B) 5x105 BMMφ were plated and 
infected with Pru (MOI 1:1) for 24 hrs following overnight stimulation with TNF-α (10 
fold dilutions, beginning at 100 Units/mL) and IFN-γ (10 fold dilutions, beginning at 100 
Units/mL).  C) Supernatants from (A) were measured for nitrite (nitric oxide) production 
following the Griess reaction protocol. D,E) 106 BMMφ were treated with IFN-γ (100 
Units/mL) for the indicated time points and analyzed by western blot for pSTAT1, 
IRGM1, IRGM2, IRGM3, IRGD, IRGA6, and IRGB6.   F) 106 peritoneal cells from 
control and LysM-cre Socs3fl/fl infected with Pru for 4 days were plated on coverslips and 
stained for Irgm3 and visualized as described in the methods. Western blots were 
performed by Carolyn M. Gray. 
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Figure 17. IL-6 does not have altered signaling effects in LysM-cre Socs3fl/fl 
macrophages.  In order to determine if IL-6 has signaling differences in the absence of 
SOCS3, wild type and SOCS3-deficient macrophages were analyzed for the ability of IL-
6 to prevent microbicidal activity as well as to signal through STAT1, STAT3, and ERK. 
A) 106 BMMφ were infected with 1:1 Pru for 24 hours in the presence of IFN-γ/LPS with 
or without IL-6 (100ng/mL). B,C) 106 BMMφ were stimulated with IL-6 (100 ng/mL) for 
the indicated time points and analyzed for pSTAT3, pSTAT1, and pERK and compared 
to β-actin, total STAT3, and total ERK. Error bars +/- SD. Statistics was performed using 
Student’s t tests and results are representative of two independent experiments. Western 
blots were performed by Carolyn M. Gray. 
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IL-6 has specific inhibitory effects on macrophages 
IL-6 was shown to have inhibitory functions on macrophage killing abilities but 
these effects were not exacerbated by the absence of SOCS3.  To determine if IL-6 had 
other effects that were enhanced when SOCS3 was deleted, BMMφ were evaluated for 
their ability to produce pro-inflammatory cytokines in the presence of IL-6.  When co-
cultured with IFN-γ and LPS, IL-6 was shown to inhibit IL-12p40 production in a 
concentration-dependent manner (Figure 18A).  Additionally, LysM-cre Socs3fl/fl 
macrophages produced significantly less IL-12p40 that control macrophages and this 
initial defect could be restored when neutralizing antibodies to IL-6 were administered to 
the cultures (Figure 18B).  These data indicate that endogenous IL-6 produced in these 
cultures acts as an inhibitor of IL-12 and TNF-α (Figure 18B,C). Since IL-6 affects IL-12 
and TNF-α, other effects of IL-6 signaling were tested.  Nitrite production was found to 
be unaffected by IL-6 when IL-6 was co-cultured with IFN-γ and LPS (Figure 18D).   
Arginase is an enzyme that inhibits iNOS-mediated NO production by competing 
for available arginine stores.  Arginase I (Arg1) has also recently been linked to IL-6 
activity and it was suggested that this enzyme might play a role in macrophage signaling 
and inhibition of microbicidal function.  To test if Arg1 was differentially regulated by 
IL-6 or T. gondii, mRNA levels were measured from BMMφ after 1 hr of incubation.  
LysM-cre Socs3fl/fl macrophages were shown to express less Arg1 mRNA than control 
macrophages and these levels were unaffected by either infection or IL-6 stimulation 
(Figure 18E).  Conversely, when arginase activity was measured as consequence of urea 
output in the presence of arginine, LysM-cre Socs3fl/fl macrophages had a higher baseline 
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of activity than control macrophages (Figure 18F).  Moreover, addition of IL-4 increased 
the activity of arginase in both control and LysM-cre Socs3fl/fl macrophages as expected, 
and treatment with IL-6, IL-10 or infection with RH or Pru induced similarly higher 
levels in LysM-cre Socs3fl/fl macrophages than control macrophages (Figure 18F). These 
increased levels more likely reflect the difference in baseline arginase activity and not a 
differential effect of the stimuli in LysM-cre Socs3fl/fl macrophages.  Overall, it appears 
that LysM-cre Socs3fl/fl macrophages may have increased arginase activity relative to 
mRNA expression, although without a phenotype of impaired microbicidal activity or 
NO production, it is difficult to ascertain the biological significance of these findings. 
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Figure 18.  IL-6 specifically inhibits IL-12 and TNF-α  production from stimulated 
macrophages. SOCS3 has been described to limit IL-6 signals.  Therefore, the ability of 
LysM-cre Socs3fl/fl macrophages to produce pro-inflammatory cytokines in the presence 
of IL-6 was evaluated.  A) The ability of IL-6 to inhibit IL-12p40 production was 
evaluated by stimulating 2x105 BMMφ with IFN-γ and LPS (10 Units/mL and 10 ng/mL 
respectively) with or without increasing concentrations of IL-6 (0.001 to 10 ng/mL, 10 
fold dilutions) for 24 hrs and analyzed by ELISA. B,C) 2x105 BMMφ were given IFN-γ 
and LPS with or without α-IL-6 and analyzed for IL-12p40 and TNF-α production. D) 
Similar to (A), nitric oxide was measured from stimulated control and LysM-cre Socs3fl/fl 
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macrophages in the presence of increasing concentrations of IL-6.  E) mRNA was 
measured from 106 BMMφ stimulated with IL-6 or infected with either strain of parasite 
for 60 min. F) Arginase activity was measured as Urea output as described in the 
Methods section for the indicated conditions and light was measured at 540 nM and set to 
relative units. Statistics were performed using Student’s t tests and results are 
representative of two independent experiments. Mean +/- SD. 
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Neutralization of IL-6 restores the immune response to T. gondii in LysM-
cre Socs3fl/fl mice 
The data described above indicate that, consistent with previous studies, in the 
absence of SOCS3 IL-6 becomes a potent antagonist of IL-12 production. To directly test 
whether endogenous IL-6 contributed to the observed susceptibility of LysM-cre Socs3fl/fl 
mice, Socs3fl/fl and LysM-cre Socs3fl/fl mice were treated with neutralizing antibodies to 
IL-6.  When these mice were evaluated for survival, control mice given the α−IL-6 
treatment survived up to 40 days after challenge (Figure 19A) whereas LysM-cre Socs3fl/fl 
mice treated with rat IgG succumbed acutely to T.gondii.  However, when these mice 
were treated with α−IL-6, 80% of the mice survived acute challenge and progressed into 
the chronic phase of this infection (Figure 19A). Analysis of treated mice revealed that 
addition of α−IL-6 resulted in a marked reduction in the number of infected cells in the 
peritoneal cavity at day 8 in Socs3fl/fl and LysM-cre Socs3fl/fl mice (p<0.001, Figure 19B).  
Similarly, IL-6 and IFN-γ levels were significantly decreased in the peritoneum of 
Socs3fl/fl and LysM-cre Socs3fl/fl mice (p<0.001) at day 4 post-infection with trends 
towards a similar decrease in IL-12p40, IL-10, and IL-17 (Figure 19C-G).  No difference 
in IL-12p40, IFN-γ, or IL-10 could be detected in the sera at day 4 (Figure 19H-J).  A 
reduction in cytokine production was observed following α-IL-6 treatment that is likely 
the direct result of an overall decrease in cellular recruitment and specifically CD4+ and 
CD8+ T cell and to the peritoneal cavity associated with reduced parasite burdens (Figure 
19K-M).  There was also a decrease in the total number of IFN-γ-producing T cells 
(Figure 19L,M) as well as a trend towards fewer IL-12p40- and TNF-α-producing 
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monocytes and neutrophils following α-IL-6 treatment (Figure 19N,O).   These data 
provide evidence that overall inflammation and parasite burdens are reduced following α-
IL-6 treatment. 
Given the reduced inflammation following α-IL-6 treatment, it is difficult to 
determine if this antibody treatment restores IL-12 production using an infectious model.  
Therefore, to confirm that neutralizing IL-6 in vivo elicits better IL-12 responses, a non-
infectious model using thioglycollate macrophages was used.  When LysM-cre Socs3fl/fl 
mice were given rat IgG, isolated thioglycollate-elicited macrophages from the peritoneal 
cavity demonstrated impaired IL-12p40 and TNF-α production as compared to control 
mice (Figure 20A,B).  This effect was reversed when these mice were treated with 
neutralizing antibodies to IL-6.  Overall, these data suggest that IL-6 is an inhibitor of 
inflammatory macrophages responses during toxoplasmosis and that LysM-cre Socs3fl/fl 
mice are hypersensitive to these effects. 
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Figure 19.  Administration of neutralizing antibodies to IL-6 reduces parasite 
burdens and overall inflammation in LysM-cre Socs3fl/fl mice.  
In vivo neutralization of IL-6 reduces acute mortality of infected LysM-cre Socs3fl/fl mice 
that correlates with reduced parasite burdens and indicators of Th1 inflammation. (A-D) 
200 µg/mouse of rat IgG or α-IL-6 was administered i.p. to 5 mice per group on the day 
preceding infection as well as 2 days post infection with 104 Pru parasites. (A) Mice were 
sacrificed at day 8 p.i. and analyzed for IL-6 by ELISA to confirm neutralization. (B) 
Survival of infected mice was performed on 5 mice per group and carried out to 40 days. 
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(C) The percentage of infected cells in the peritoneal cavity was measured similarly to 
Figure 2C and described in the methods.  (D) IL-12p40 and IFN-γ production was also 
measured in the peritoneum as described in Figure 5 and the methods. (E) Thioglycollate-
elicited macrophages were used to determine if a-IL-6 treatments could restore IL-12 
production from LysM-cre Socs3fl/fl macrophages. IL-12p40 was measured by ELISA 
from 24 hr cultures of 2.5x105 thioglycollate-elicited macrophages isolated from the 
peritoneal cavity on day 4 following the antibody regimen described above. Experiments 
were repeated twice. One-Way ANOVA followed by student’s t test was used to 
determine statistical significance. 
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Figure 20.  Neutralizing antibodies to IL-6 restores pro-inflammatory function of 
thioglycollate-elicited macrophages in LysM-cre Socs3fl/fl mice. Inflammatory 
monocytes and neutrophils demonstrate a defect in production of IL-12p40 and TNF-α.  
To determine if this effect can be restored in vivo with when IL-6 is blocked, 
inflammatory macrophages were elicited with thioglycollate (n=3 per group).  A,B) After 
4 days, peritoneal cells were isolated and plated for 24 hours and measured for IL-12p40 
and TNF-α.  While blocking IL-6 had little effect on macrophages elicited from control 
mice, it significantly enhanced the ability of macrophages from LysM-cre Socs3fl/fl mice 
to produce IL-12p40 and demonstrate a trend, though not statistically significant, towards 
restoration of TNF-α production.  These data indicate that IL-6 blocks pro-inflammtory 
responses from macrophages in vivo. Results are indicative of two experiments. Mean +/- 
SD. 
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Neutralizing antibodies to IL-10R reduces parasite burden and inflammation 
in LysM-cre Socs3fl/fl mice 
Neutralizing antibodies to IL-6 enhance anti-parasitic mechanisms by preventing 
IL-6 from inhibiting IL-12 production from macrophages and neutrophils.  IL-10 is 
another cytokine that signals through STAT3 and has significant inhibitory functions on 
APCs 268, 269. To determine if blocking IL-10 signaling would induce a similar reduction 
in parasite replication as IL-6, Socs3fl/fl and LysM-cre Socs3fl/fl mice were infected with 
Pru and treated with α-IL-10Rα antibodies the day before and two days following 
infection.  At day 8 post-infection, the total number of PECs demonstrated a trend 
towards fewer inflammatory cells following α-IL-10Rα treatment although this was not 
significant (Figure 21A).  In control mice, there was a moderate reduction in the number 
of infected cells in the peritoneum following treatment (Figure 21B).  However, there 
were significantly fewer infected cells in LysM-cre Socs3fl/fl mice given α-IL-
10Rα (p<0.001) that was associated with fewer CD4+ and CD8+ T cells in control mice 
with a similar trend in LysM-cre Socs3fl/fl mice (Figure 21C). To determine if pro-
inflammatory cytokines were enhanced following α-IL-10Rα treatment, IL-12p40 and 
IFN-γ were measured from the sera of day 7 infected Socs3fl/fl and LysM-cre Socs3fl/fl 
mice.  While IFN-γ levels were unaffected by treatment with α-IL-10Rα, IL-12p40 levels 
were enhanced in the sera of LysM-cre Socs3fl/fl mice (p<0.05) with a similar trend in 
control mice (Figure 21D,E).  Curiously, blocking the IL-10R also increased the IL-10 
that could be detected in the sera (Figure 21F).  The most likely explanation for the 
observed increase in IL-10 is that blocking the IL-10R prevents IL-10 from being 
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endocytosed by cells therefore increasing its concentration in the sera.  However, overall 
these data demonstrate that treatment with α-IL-10Rα reduce parasite burdens and 
inflammation in both control and LysM-cre Socs3fl/fl mice.
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Figure 21. Neutralization of IL-10 signaling significantly reduces parasite burden 
and inflammation in LysM-cre Socs3fl/fl mice.  Addition of blocking antibodies to IL-6 
rescues lethality in LysM-cre Socs3fl/fl mice.  To determine if this effect could be 
reproduced using neutralizing antibodies another inhibitory cytokine, IL-10, that also 
signals through STAT3, infected control and LysM-cre Socs3fl/fl mice were treated with α-
IL-10Rα antibodies.  Treated and untreated mice were then evaluated for parasite burden 
and markers of inflammation. A) LysM-cre Socs3fl/fl mice recruited a similar number of 
cells to the peritoneum as Socs3fl/fl mice at 7 days post-infection and these numbers were 
reduced following treatment with α-IL-10Rα.  B) The number of infected cells was 
significantly greater in untreated LysM-cre Socs3fl/fl mice than Socs3fl/fl mice (p<0.001) 
following infection.  Upon treatment with α-IL-10Rα, there was a slight reduction in 
infected cells in Socs3fl/fl mice and a large reduction in the number of infected cells in 
LysM-cre Socs3fl/fl mice (p<0.001). C) This reduction in parasite load corresponded with a 
decrease in the number of CD4+ and CD8+ T cells in the peritoneum of Socs3fl/fl mice and 
a similar trend in LysM-cre Socs3fl/fl mice. D-F) Concentrations of IL-12p40, IFN-γ, and 
IL-10 were measured from the sera of day 7 infected mice.  Following treatment with α-
IL-10Rα, there was a significant increase in IL-12p40 in the sera from LysM-cre Socs3fl/fl 
mice with a similar trend in Socs3fl/fl mice.   IFN-γ levels remained similar following 
treatment and there was an increase in detectable IL-10, although this was not statistically 
significant. 
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Addition of IL-12 rescues lethality in LysM-cre Socs3fl/fl mice 
LysM-cre Socs3fl/fl mice succumb to infection from T. gondii infection associated 
with diminished IL-12 production by macrophages and neutrophils.  To determine if 
LysM-cre Socs3fl/fl mice could survive challenge when provided with exogenous IL-12, 
mice were infected and given 200 ng of IL-12 i.p. for 5 days. By day 7, untreated LysM-
cre Socs3fl/fl mice were moribund and one had died while all control mice and treated 
LysM-cre Socs3fl/fl mice did not show the effects (Figure 22A).  Untreated LysM-cre 
Socs3fl/fl mice had significantly higher parasite burdens and these were associated with an 
8% loss in body weight while IL-12-treated LysM-cre Socs3fl/fl mice appeared healthy and 
lost significantly less weight by day 6 (Figure 22B,C).  Addition of IL-12 reduced 
parasite burden and prevented the loss of body weight in LysM-cre Socs3fl/fl mice (Figure 
22B,C) Further analysis on days 4 and 7 showed that IL-12 treatment resulted in a 
dramatic reduction in parasite DNA in the liver compared to untreated LysM-cre Socs3fl/fl 
mice (Figure 22D). While the overall numbers of spleen and PECs were unaffected by 
IL-12 treatment, there was a significant reduction in the number of CD4+ cells following 
treatment with a similar trend in decreased CD8+ T cell, NK cell, neutrophil, and 
monocyte populations in the peritoneum at day 4 (Figure 22E-G).  This reduction of 
cellularity was associated with a similar trend in IFN-γ, IL-12p40, IL-6, IL-10, and IL-17 
production in the peritoneum although these levels were not statistically significant 
(Figure 22H).  IL-12p40 and IFN-γ levels were significantly decreased in the sera 
following IL-12 treatment (Figure 22I) indicating that treatment of infected LysM-cre 
Socs3fl/fl mice with IL-12 is sufficient to reduce parasite burden and overcome the 
inhibitory actions of IL-6. 
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Figure 22. Addition of IL-12 early during T. gondii infection reduces parasite 
burden and overall inflammation.  In order to determine if addition of IL-12 during 
acute infection could rescue lethality, control and LysM-cre Socs3fl/fl mice were infected 
with Pru and given PBS or IL-12p70 (200µg/mouse) every day for the first five days for 
survival and for days 0-3 for analysis of day 4 infected animals.  A) Untreated LysM-cre 
Socs3fl/fl mice were moribund on day 7 post-infection with one mouse succumbing to 
infection.  All other groups appeared normal and showed no signs of clinical TE.  B) 
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Addition of IL-12 was associated with significantly decreased numbers of infected cells 
in the peritoneal of both control and LysM-cre Socs3fl/fl mice.  C) IL-12 addition also 
resulted in a significant loss of weight by day 6 post-infection in LysM-cre Socs3fl/fl mice 
(p<0.05).  D) Addition of IL-12 reduced the parasite burden in the livers of LysM-cre 
Socs3fl/fl mice at day 4 and day 7 post-infection despite no change in overall PEC and 
spleen numbers (E).  This decrease in parasite burden was associated with diminished 
inflammation.  CD4+ T cells were fewer in IL-12-treated LysM-cre Socs3fl/fl mice (F) and 
a trend toward fewer CD8+, neutrophils, inflammatory, monocytes, and NK cells 
although not statistically significant (F,G).  Addition of IL-12 also reduced IFN-γ and IL-
12p40 levels in the sera with trends towards lower concentrations of IL-12p40, IFN-γ, IL-
6, IL-10, and IL-17 in the peritoneum and sera (H,I). 
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Vaccination can rescue lethality in LysM-cre Socs3fl/fl mice 
 LysM-cre Socs3fl/fl mice succumb to T. gondii infection associated with large 
parasite burdens as a result of impaired IL-12 responses.  Both IL-10 and IL-6 inhibit IL-
12 production from macrophages and removal of the ability of these cytokines to function 
restores protective responses and reduces parasite burdens.  Addition of IL-12 also 
protects LysM-cre Socs3fl/fl mice indicating that SOCS3 is an important regulatory protein 
that prevents the inhibition of IL-12 by IL-6 specifically. To better understand how 
SOCS3 in macrophages promotes a protective response, Socs3fl/fl and LysM-cre Socs3fl/fl 
mice were vaccinated with a replication-deficient strain of T. gondii, CPSII for 1 week 
prior to challenge with Pru.  As expected, control mice survived challenge out to 25 days 
while LysM-cre Socs3fl/fl mice succumbed to infection by day 10 (Figure 23A).  
Vaccination of LysM-cre Socs3fl/fl mice, however, resulted in protection from acute 
susceptibility by T. gondii.  This suggests that while IL-12 production is required for 
acute protection in LysM-cre Socs3fl/fl mice, these mice can be primed through other 
mechanisms such a humoral responses to promote resistance.  
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Figure 23.  Vaccination with a replication deficient strain of T. gondii protects 
LysM-cre Socs3fl/fl from lethal challenge.  To determine if LysM-cre Socs3fl/fl mice can 
be primed to resist lethal challenge, control and LysM-cre Socs3fl/fl mice (n=5) were 
infected with 106 CPSII parasites for 1 week prior to infection with 104 Pru and 
monitored for survival out to 25 days post-infection (A).  This experiment was repeated 
twice with similar results. 
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Discussion  
Several reports have highlighted the ability of T. gondii to induce the 
phosphorylation of STAT3 in macrophages and that this is associated with the ability to 
suppress the production of TNF-α and IL-12 87, 270. More recently this phenomena has 
been linked to the activity of a parasite kinase, ROP16, that is injected into the host cell 
cytoplasm and which can directly phosphorylate STAT3 and leads to its activation 86, 87.  
How infection-induced STAT3 activation limits cytokine production remains unclear but 
the observation that T. gondii also upregulates SOCS3, a well characterized target of 
STAT3 linked to inhibition of cytokine signaling, suggested that this may be part of the 
mechanism that allows this pathogen to suppress cytokine production.  However, in vitro 
studies revealed that SOCS3 was not required for the ability of T. gondii to limit 
macrophage production of cytokines. Rather, these in vivo studies using the LysM-cre 
Socs3fl/fl mice revealed that SOCS3 was essential for the innate response required for the 
initial control of T. gondii. In these mice, the LysM promoter drives expression of Cre 
recombinase in neutrophils and monocytes/macrophages, two cell types that have major 
roles in the early response to T. gondii 108, 109, 309. These two populations represent a major 
source of cytokines early in infection and in the absence of SOCS3 this acute response 
was severely compromised and associated with an inability to control T. gondii.  
While relatively few studies have addressed the role of SOCS3 in resistance to 
infection, the ability of this protein to limit cytokine signaling through the receptor gp130 
has been described in detail and is reviewed elsewhere 312. Thus, while many cytokines, 
such as IL-6 and IL-10 can activate STAT3 and upregulate SOCS3, this inhibitory 
protein binds directly to the gp130 subunit of the IL-6 receptor complex but not the IL-
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10R and so SOCS3 acts to inhibit IL-6 but not IL-10 signaling 267, 313. However, data 
presented here show that the absence of SOCS3 resulted in enhanced T. gondii-induced 
STAT3 signaling.  This suggests that either the ROP16 secreted by T. gondii following 
infection associates with the gp130 subunit and is inhibited by SOCS3 similarly to an IL-
6 stimulus or that SOCS3 has an additional mechanism to limit phosphorylation of 
STAT3. Thus, the ROP16-mediated mechanism by which T. gondii activates STAT3 may 
be more complex than just direct phosphorylation of this substrate. 
The significance of the specific inhibitory action of IL-6 has been highlighted in 
multiple reports that in the absence of SOCS3, IL-6 provides a sustained STAT3 signal 
that mimics effects observed with IL-10 and that IL-6 now becomes a potent inhibitor of 
macrophage production of TNF-α and IL-12 87, 270, 313.  Furthermore, α-IL-6 added to 
cultures of stimulated SOCS3-deficient stimulated macrophages completely restored IL-
12p40 production, enhancing the level of secreted cytokine over IFN-γ/LPS stimulation 
alone.  This implies that the endogenous IL-6 produced is an antagonist in these cultures. 
Consistent with this observation, the neutralization of IL-6 in the LysM-cre Socs3fl/fl mice 
allowed these mice to control the acute challenge with T. gondii and develop the 
protective responses required for long-term resistance to this infection. Thus, it appears 
that in the absence of SOCS3, early IL-6 produced during toxoplasmosis has a profound 
inhibitory effect on the acute innate responses.  This observation is consistent with 
another report in which LysM-cre Socs3fl/fl mice treated with a lethal dose of LPS had 
limited TNF-α production and survived the sepsis caused by excessive inflammation 267. 
One of the themes that emerged from these studies was that IL-6, even in wild 
type cells, has significant but specific inhibitory effects. For example, when wild type 
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macrophages were treated with IL-6, their ability to produce IL-12p40 was selectively 
inhibited in a dose-dependent manner while other inflammatory molecules such as nitric 
oxide were unimpaired.  Additionally, when control mice were treated with neutralizing 
antibodies to IL-6, their ability to control early parasite replication was enhanced 
suggesting that IL-6 is a natural inhibitor of the innate mechanisms that contribute to 
early control of T. gondii. Indeed, similar to the studies presented here, the use of 
monoclonal antibodies to neutralize IL-6 in chronically infected wild type mice resulted 
in improved control of T. gondii but the basis for this effect was not understood 180. IL-6, 
similarly to IL-10, can antagonize the ability of IFN-γ-activated macrophages to limit the 
intracellular replication of T. gondii, L. amazonensis, and M. tuberculosis and this effect 
seems to be exacerbated in the absence of SOCS3 294, 296, 304. Thus, based on the in vitro 
studies, the ability of IL-6 to antagonize the anti-microbial effects of IFN-γ might have 
explained how despite high systemic levels of IFN-γ during infection, LysM-cre Socs3fl/fl 
mice were unable to control parasite burdens because their macrophages and neutrophils 
were unable to respond properly to IFN-γ. Moreover, the observation that the percentage 
of macrophages and neutrophils infected with T. gondii is identical between control and 
LysM-cre Socs3fl/fl mice indicates that the absence of SOCS3 does not result in a cell 
intrinsic defect in the ability to control T. gondii. Together, these data suggest that 
SOCS3-deficient macrophages can control parasite replication adequately when provided 
the proper signals and that the enhanced susceptibility observed in the absence of SOCS3 
is a consequence of altered innate responses. 
While this study has focused on the contribution of IL-6 to the regulation of 
inflammatory responses during toxoplasmosis, this cytokine is also important in many 
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other infectious settings. As previously mentioned, IL-6 promotes growth of Leishmania, 
T. gondii, and Mycobacterium spp. 294-296, 304 and human IL-6 has also been shown to be 
associated with both enhanced lytic replication of Human Herpes Virus-8 (HHV-8) and 
exacerbated disease of patients co-infected with HIV 314.  Also, HHV-8 encodes a viral 
IL-6 gene that has been shown to impair neutrophil recruitment and promote viral growth 
in vitro 315, 316. Together, these studies highlight how multiple infectious agents can utilize 
this pathway to promote their own survival by affecting inflammatory signals.  From a 
host perspective, resistance to many pathogens is characterized by the need to balance the 
development of a strong cell mediated immune response with the ability to limit 
collateral damage caused by the immune system.   Indeed, there are many examples of 
inhibitory cytokines such as IL-10, TGF-β, and IL-27 that are essential to inhibit 
infection-induced immune hyperactivity 22, 25, 317 and the SOCS proteins also limit signals 
that promote excessive inflammation. SOCS1 is best described as a regulator of Type I 
and II IFN-mediated phosphorylation of STAT1 318, 319 and has been shown to diminish 
IFN-γ responsiveness to T. gondii,, L. major, and Hepatitis C Virus 290, 320-322.  However, 
while SOCS3 may have a role in limiting IFN responses, its main role during T. gondii 
infection, and possibly other intracellular pathogens, is to limit the anti-inflammatory 
actions of IL-6 including its ability to antagonize IL-12 production.  Thus, SOCS3 
differentiates itself from other SOCS family members and its signaling pathway can be 
considered among those that promote proper and effective Th1 immunity. 
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Chapter IV.   
 
T. gondii structural proteins such as PHIL1 and AMA1 
affect the speed of parasite invasion leading to increased 
recognition by the immune system. 
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Abstract 
The inner membrane complex (IMC), a series of flattened vesicles at the 
periphery of Apicomplexan parasites, is thought to be important for parasite shape, 
motility and replication, but only a few of the proteins that associate with the IMC and 
function in these processes have been identified. TgPHIL1 and AMA1 are two such 
proteins.  TgPHIL1, a Toxoplasma gondii protein, associates with the IMC and/or 
underlying cytoskeleton and is concentrated at the apical end of the parasite while Apical 
Membrane Antigen 1 (AMA1) is a microneme protein thought to also be involved in 
motility and invasion. Orthologs of both proteins are found in other Apicomplexans, but 
their functions are largely unknown. TgPHIL1 knockout parasites have a distinctly 
different morphology than wild-type parasites, and normal shape is restored in the 
knockout background by expression of the wild-type allele. The knockout parasites are 
outcompeted in tissue culture by parasites expressing functional TgPHIL1, and the 
knockouts generate reduced parasite loads in the spleen and liver of infected mice.  
Conditional deletion of AMA1 reduces fitness in vitro and also leads to impaired growth 
and enhanced host microbicidal activity in vivo.  These findings demonstrate a role for 
both AMA1 and TgPHIL1 in the morphology, growth and fitness of T. gondii 
tachyzoites. 
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Introduction 
 The Phylum Apicomplexa contains a number of medically important parasites 
including Cryptosporidium spp., which cause diarrheal illness in children and immuno-
compromised patients, Plasmodium spp., which are the causative agents of malaria, and 
T. gondii, which causes life-threatening disease in immuno-compromised individuals and 
the developing fetus. Although these organisms have been studied for decades, much of 
their basic biology is unknown despite their significance to human and veterinary disease. 
Because T. gondii is easily grown and is genetically tractable, it provides a robust tool 
that allows for study of many aspects of Apicomplexan biology. 
 One unique feature of the Apicomplexans is the presence of an inner membrane 
complex (IMC) which is located beneath the plasma membrane of the parasite.  The IMC 
is a series of flattened vesicles that comprise the pellicle along with the IMC. Directly 
beneath the IMC is an intertwining series of intermediate filament-like proteins called the 
subpellicular network 323, 324. Various functions for the IMC and the subpellicular 
network have been suggested 323. During parasite replication, the IMC forms early and 
may provide a scaffold for tachyzoite assembly or possibly to stabilize mature 
tachyzoites. Additionally, some components of the myosin motor complex, necessary for 
motility and invasion, are anchored in the IMC 325. Localization of the motor complex 
between the outer membrane of the IMC and the plasma membrane is thought to be 
critical for motility and invasion. While one member of the myosin motor complex, 
GAP45/70, appears to physically connect the IMC to the plasma membrane, the detailed 
mechanism by which the IMC, subpellicular network and subpellicular microtubules 
associate with each other and are organized within the pellicle have yet to be identified 
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326.  
  TgPHIL1 (Photosensitized INA-Labeled protein 1) was previously reported to 
localize to the parasite periphery, and remain concentrated at the apical end directly 
posterior to the conoid, a cone-shaped structure composed of a novel polymeric form of 
tubulin 63. TgPHIL1 is highly conserved among members of the phylum Apicomplexa 
but demonstrates little homology to proteins in other phyla. When parasites were treated 
with Clostridium septicum alpha-toxin, which causes the plasma membrane to swell away 
from the IMC, TgPHIL1 remained associated with the IMC and/or associated 
cytoskeletal structures 63. Although TgPHIL1 labeling with INA suggests this protein is 
membrane associated, TgPHIL1 is also highly insoluble and extracts much like a 
cytoskeletal protein 63.  In order to identify the function of TgPHIL1, parasites containing 
a TgPHIL1 deletion were generated. Phenotypic analysis of the knockout parasites 
revealed that TgPHIL1 is necessary for maintaining the distinctive shape of T. gondii 
tachyzoites, and parasites lacking TgPHIL1 show both a growth defect in culture and 
reduced fitness in a mouse model of infection (Barkhuff, in press). 
 Similar to TgPHIL1, Apical membrane antigen-1 (AMA1) is a microneme protein 
that is highly conserved among Apicomplexan parasites and seems to be involved in 
parasite motility and invasion 327, 328.  Since its initial discovery 15 years ago, AMA1 has 
received considerable attention as a malaria vaccine candidate 329-331. AMA1 proteins are 
transmembrane proteins, with a short C-terminal cytoplasmic tail and a large N-terminal 
extracellular domain 327, 329-332. Like other microneme proteins, AMA1 is secreted onto 
the parasite surface, where its ectodomain is proteolytically cleaved and shed 64, 327, 333. 
Additonally, antibodies against AMA1 inhibit invasion of apicomplexans supporting a 
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role for this protein in motility and dissemination  67, 327, 334-336.   
 Deletion of AMA1 from T. gondii renders the parasite unviable and unable to 
replicate 337. Therefore, the development of a system for conditional gene expression in T. 
gondii has made it possible to study the function of AMA1 by reverse genetics 338. The 
Ward laboratory generated a conditional mutant of AMA1 where the protein is repressed 
following tetracycline treatment in vitro or when tetracycline is administered in the 
drinking water of infected mice 337. Using this conditional expression system to generate 
a transgenic parasite line in which the levels of T. gondii AMA1, expression can be 
manipulated and shows that TgAMA1-depleted parasites are impaired in their ability to 
attach intimately to host cells and to regulate rhoptry secretion 327, 337.   
 Transgenic AMA1 parasites were generated from the RH strain that is extremely 
virulent with an LD100 of 1 parasite 75.  When wild type mice were challenged with this 
strain of parasite, they succumbed to infection with similar kinetics to RH. When 
tetracycline was administered in the drinking water to mice following infection, AMA1 
was repressed and there was a dramatic reduction in parasite load indicating that AMA1 
is involved in parasite replication and/or host evasion in vivo. 
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Materials and Methods 
Culture of parasites  
Wild-type RH strain T. gondii was maintained by serial passage in confluent primary 
human foreskin fibroblast (HFF) cells in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented 10% heat inactivated fetal bovine serum (FBS), 10 units/ml penicillin G, 
10 g/ml streptomycin sulfate, and 10 mM HEPES buffer, as previously described.  
TgPHIL1 parasites were generated in the Ward laboratory using the following conditions. 
In order to generate the TgPhIL1 knockout construct, PCR was performed on T. gondii 
genomic DNA using primers PhIL15’KOfor 
(5’GCTGAGGAGGGGAAGAAGATCGAG3’) and PhIL13’KOrevXbaI 
(5’TGCTCTAGATATCCGCAAATGCTCGCTCGCC3’) to generate a 6.5 kb amplicon 
containing 2.9 kb of TgPhIL1 5’ flanking sequence, the 1.3 kb TgPhIL1 open reading 
frame (ORF), and 3.1 kb of TgPhIL1 3’ flanking sequence.  The amplified product was 
cloned into pCR-Blunt TOPO (Invitrogen) and inverse PCR was performed with primers 
KOinvfor (5’AGGAGTGTTCATGTTGTTTGCTG3’) and KOinvrev 
(5’TGAATTCGTCTAATCCAGAGTCTGTC3’) to remove the TgPhIL1 ORF.  The ble 
cassette was digested from pGRA1/ble  with HindIII and XbaI and the ends were filled in 
with Klenow, followed by blunt ligation to the inverse PCR product in order to generate 
the knockout construct p∆PhIL1/ble.  The plasmid was linearized with Not1 and 
transfected into RH parasites. The transfected parasites were added to confluent HFF 
cells and selected with phleomycin as described previously 339.  Individual clones were 
isolated by limiting dilution and clones lacking TgPhIL1 expression were identified by 
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immunofluorescence with anti-TgPhIL1 63.  AMA1 parasites were also generated in the 
Ward laboratory under the following conditions and published in 337.  Briefly, The 
TgAMA1 open reading frame with a C-terminal myc tag was inserted in p7TetOS1 
downstream of the inducible promoter, and a chloramphenicol acetyl transferase cassette 
was inserted upstream, generating p7TetOS1/AMA1-myc/CAT. Transactivator-
expressing parasites, designated here as “AMA1” parasites, were transfected with 
p7TetOS1/AMA1-myc/CAT. Parasites harboring the construct were selected with 
chloramphenicol and cloned by limiting dilution. Positive clones were identified by SDS-
PAGE/Western blotting and immunofluorescence microscopy with monoclonal 
antibodies (mAbs) against TgAMA1 (B3.90,64) and against myc (9E10, Clontech). The 
clone expressing the highest level of Atc-regulatable, properly localized TgAMA1-myc 
(designated “AMA1/AMA1-myc”) was used to generate the TgAMA1 knockout. 
 
Mice and infections 
Female 6 to 8 week old C57BL/6 mice were obtained from Jackson Laboratories (Bar 
Harbor, ME) and maintained under specific-pathogen-free conditions in accordance with 
institutional guidelines. 5 mice per group were infected intraperitoneally with 200 ml of 
PBS containing 104 RH or RH!TgPHIL1 tachyzoites. Peritoneal cells were harvested on 
day 7 by lavage with cold PBS, spun onto coverslips and stained using the HEMA-3 kit 
(Fisher Scientific) as directed by the manufacturer. Parasite DNA levels were measured 
by real time PCR on DNA isolated from liver and spleen samples 7 days post-infection 
using the High Pure PCR Template Purification Kit (Roche). The tandemly arrayed, 35-
fold-repetitive T. gondii B1 gene was amplified by real-time PCR (Forward 5’- 
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TCCCCTCTGCTGGCGAAAAGT-3’; Reverse 5’ 
AGCGTTCGTGGTCAACTATCGATTG-3’) using the AB7500 fast real-time PCR 
thermal cycler and Power SYBR green reagents (Applied Biosystems, Foster City CA). 
Quantitect primers for the mouse housekeeping gene β-actin (Qiagen, Valencia CA) were 
used as a normalization control. The cycle numbers were normalized relative to their 
individual actin signals and these were averaged among the 5 mice per group; 
RHTgPHIL1 was set to 1. 
 
Tetracycline administration 
Groups of 5 C57/Bl6 mice were infected with 104 AMA1 or 2F12 parasites and either 
received sterile drinking water supplemented with 0.1% sucrose (AMA1 or 2F12) 
drinking water was further supplemented with 0.2 mg/ml ATc (+ATC).  This water was 
replenished, if exhausted, throughout the duration of the experiment. 
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Results 
PHIL1-knockout parasites have decreased survival and altered morphology 
in vivo. 
TgPHIL1-knockout parasites are outgrown by wild-type RH parasites in vitro 
(Barkhuff, in press). In order to determine if there is a growth difference in vivo, mice 
were infected intraperitoneally with 104 wild-type or TgPHIL1 tachyzoites.  Mice 
infected with either strain succumbed to infection around 7-8 days post-infection (Figure 
24A).  Seven days post-infection, large numbers of RH parasites were observed in the 
peritoneum and significantly fewer free and intracellular parasites were detected in the 
peritoneum of mice infected with the TgPHIL1 parasites (Figure 24B).  The spleen and 
liver were also harvested seven days after infection, and quantitative PCR (qPCR) was 
performed to quantify parasite DNA.  Higher concentrations of parasite DNA were 
detected in the spleen and liver of mice infected with wild-type parasites than with 
TgPHIL1 parasites, particularly in the spleen, where there is a four-fold decrease in 
knockout parasites as compared to wild-type parasites (Figure 24C,D).  These data 
demonstrate that the PHIL1 knockout parasites exhibit a reduced ability to survive and/or 
disseminate in mice when compared to wild-type parasites.   
TgPHIL1, demonstrate an impaired ability to migrate in vitro indicating that this 
PHIL1 is involved in motility and dissemination (Barkhuff, in press).  PHIL1 is also a 
structural protein and these knockout parasites appear misshapen when viewed by light 
microscopy. To further investigate if the decreased fitness of TgPHIL1 parasites is due to 
an altered morphology in vivo, RH and TgPHIL1 parasites were measured for their area 
and diameter.  Cytospins of peritoneal cells from day 7 infected mice were examined by 
microscopy.  RH-infected mice had more free tachyzoites than TgPHIL1-infected mice 
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although heavily-infected cells could be visualized in these mice as well (Figure 24E).  
Higher magnification of these cells indicated that these parasites had a larger, more 
rounded phenotype and this was reflected in the total volume (area) and diameter of each 
parasite (p<0.002, p<0.05 respectively, Figure 24 F,G). These data indicate that TgPHIL1 
parasites have altered morphology in vivo and suggest that these parasites replicate and 
survive less efficiently in the host 
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Figure 24.  TgPHIL1 parasites have decreased survival and altered morphology in 
vivo.  In order to determine if TgPHIL1 parasites have reduced fitness in vivo, C57/Bl6 
mice (n=5) were infected with either RH or TgPHIL1 and monitored for survival or 
sacrificed for parasite burdens and morphology.  A) Mice succumbed to TgPHIL1 
parasites with similar kinetics to RH infection.  B) The number of infected cells in the 
peritoneum of mice infected with TgPHIL1 was significantly lower than with RH 
although this did not affect survival (p<0.01).  C,D) Parasite DNA was significantly 
lower in the spleen (p<0.01) of mice infected with TgPHIL1 with a similar trend toward 
less parasite burden in the liver.  To assess the morphology of parasites in vivo, PECs 
from day 7 infected mice were cytospun onto coverslips, stained, and visualized by light 
microscopy.  E,F) Peritoneal cells were visualized by microscopy from day 7 infected 
mice at 20X (E) and an enhanced magnification of a representative parasite.  Arrows 
indicate free tachyzoites in RH infected cells on the left and a representative heavily-
infected cell from the peritoneum of mice infected with TgPHIL1 (F).  RH-infected mice 
have more free tachyzoites and overall parasites while TgPHIL1 have fewer free 
tachyzoites.  G) Analysis of the diameter of each parasite as well as each parasite’s total 
area was analyzed from >60 parasites from RH- and TgPHIL1-infected mice.  Results are 
indicative of two independent experiments.  Results +/-SD. 
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TgPHIL1 parasites induce similar inflammatory responses as wild-type RH 
parasites 
 Studies from the Ward lab demonstrate that TgPHIL1 parasites possess growth 
and motility defects in vitro compared to RH (Barkhuff, in press).  Moreover, mice 
infected with TgPHIL1 have lower parasite burdens associated with larger and more 
rounded parasites than mice infected with RH.  To determine if TgPHIL1 parasites 
induced a stronger inflammatory response that leads to the decreased parasite burden, 
sera was measured from infected mice to determine cytokine responses.  Sera from mice 
infected with TgPHIL1 had similar levels of IFN-γ, IL-12p40, IL-17, IL-6, and IL-10 
compared to mice infected with RH (Figure 25A).    These data indicate that enhanced 
pro-inflammatory cytokines are not responsible for either the reduced parasite burdens or 
altered morphology of TgPHIL1 parasites.  To determine if there was enhanced killing of 
TgPHIL1parasites compared to RH, Immunity-related GTPases (IRG) expression was 
measured.  IRGs are upregulated by IFN-γ and colocalize to the parasite vacuole to 
induce membrane destruction and autophagic clearance 14, 340, 341.  There are multiple 
proteins in mice and several of them are required for resistance including Irgm3 and Irga6 
13, 153, 156. Expression of Irgm3 and Irga6 in the spleen of TgPHIL1 parasites was 
comparable to RH and Irgm3 was significantly higher in the peritoneum of TgPHIL1-
infected mice (p<0.05, Figure 25B,C).  These data suggest a greater microbicidal activity 
of inflammatory cells, presumably macrophages that more effectively destroy TgPHIL1 
parasites, although this needs to be more thoroughly addressed. 
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Figure 25.  Mice infected with TgPHIL1 have similar immune responses compared 
to mice infected with RH.  TgPHIL1 have in vivo defects in replication and morphology 
that may be dictated by host immune responses.  In order to determine if a stronger 
immune response was responsible for the decreased parasite burdens observed in 
TgPHIL1-infected mice, C57/Bl6 mice were infected with RH and TgPHIL1 (n=5) and 
sera was measured for cytokine production.  A) IL-12p40, IFN-γ, IL-17, IL-10, and IL-6 
concentrations were similar between mice infected with RH and TgPHIL1.  To determine 
if other markers of inflammation were enhanced in TgPHIL1-infected mice, RNA from 
splenic and peritoneal cells from infected mice was analyzed for Irgm3 and Irga6 
expression.  B) Irgm3 expression is similar in spleen and significantly higher in the 
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peritoneum of TgPHIL1-infected mice compared to RH-infected mice.  C) Irga6 
expression is similar in the spleen and peritoneum of RH- and TgPHIL1-infected mice. 
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AMA1-deficient parasites have growth defects in vivo 
 AMA1 is a microneme protein that is highly conserved among Apicomplexan 
parasites and is involved in parasite motility and invasion in vitro 337.  To evaluate if this 
protein contributes to dissemination of the parasite in vivo, a conditional deletion of 
AMA1 was utilized.  AMA1-deleted parasites do not grow in vitro, therefore a transgenic 
parasite with a tetracycline-inducible deletion of AMA1 was utilized to measure in vivo 
effects.  Mice infected with either RH or the parental strain of AMA1 succumbed to 
infection by day 8 post-infection (Figure 26A).  Mice infected with AMA1 that were 
given anhydrous tetracycline (ATC) in the drinking water survived acute challenge.  The 
number of infected cells in the peritoneum was significantly lower in AMA1-infected 
mice as compared to RH-infected mice (p<0.01) and this was even lower in AMA1-
infected mice treated with ATC (Figure 26B). These data suggest that AMA1 is required 
for virulence in mice as its removal dramatically reduces parasite burden. 
Another clone of the AMA1 conditionally-deleted parasites, 2F12, was generated 
and these two strains were compared for their ability to induce inflammatory responses 
with or without the addition of ATC.  AMA1 and 2F12 strains both induced strong IL-
12p40, IFN-γ, and IL-17 production in the sera that were similar at day 7 post-infection. 
Addition of ATC to the drinking water dramatically decreased the cytokine production 
for both strains although in this experiment, only 2F12 levels were statistically 
significantly different (Figure 26C).  These data indicate that the removal of AMA1 from 
parasites affects their ability to replicate and disseminate rapidly and/or avoid the initial 
immune response that can limit early parasite replication.  Presumably, parasites are 
killed very early following infection before a robust Th1 response can be mounted. 
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Figure 26.  Mice infected with conditional deletions of AMA1 have increased 
survival associated with lower parasite burdens and decreased pro-inflammatory 
cytokines compared to wild type parasites.  AMA1 is associated with motility.  To 
determine if AMA1 is required for dissemination and immune evasion in vivo, C57/Bl6 
mice were infected with RH and AMA1 with or without ATC.  A) 5 mice per group were 
infected with 103 RH or AMA1 parasites and monitored for survival.  Also, ATC was 
administered to the drinking water of a cohort of RH- and AMA1-infected mice starting 
the day of infection.  All mice infected with RH succumbed to infection by day 8 as well 
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as those infected with AMA1.  Treatment of mice infected with AMA1 with ATC 
rescued the mice and these mice survived for duration of the experiment (20 days).  B) 
The number of infected cells in the peritoneum of day 7 infected mice was measured and 
there were significantly fewer parasites in in AMA1-infected mice than RH-infected mice 
(p<0.01). Treatment with ATC resulted in even lower parasite burdens as well. C) 2F12 
is a clone of AMA1 and both of these parasites lines were tested for their ability to elicit 
pro-inflammatory cytokines.  Sera from day 7 infected mice either treated with ATC or 
not was measured for the presence of IL-12p40, IFN−γ, and IL-17.  Both AMA1 and 
2F12 induce strong production of all three of these cytokines that was not significantly 
different between the strains.  Addition of ATC to mice infected with either strain 
dramatically reduced the production of cytokines, although these were only statistically 
significant for 2F12. 
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Discussion 
  Apicomplexans contain many subcellular structures and organelles that are 
involved with parasite motility and invasion. TgPHIL1 is cytoskeleton associated, 
suggesting it is involved with motility and invasion.  Although deletion of TgPHIL1 
during infection does not increase mouse resistance, these parasites have a large rounded 
morphology, disseminate less quickly, and infected mice have lower parasite burdens in 
the peritoneum and spleen.  These parasites induce similar levels of pro-inflammatory 
cytokines and slightly enhanced IRG expression suggesting that the latter may be 
involved in early clearance of the parasites.  This also suggests that the motility is linked 
to virulence and the rapidity by which a parasite replicates and disseminates in vivo is a 
strong indicator of success for the parasite 81. 
Small growth defects are likely to present a significant selective disadvantage 
over time for populations of parasites as PHIL1-deficient parasites are outcompeted by 
RH parasites in vitro (Barkhuff, in press).  It is surprising that such a dramatic decrease in 
parasite replication and dissemination by TgPHIL1 parasites does not affect susceptibility 
to the parasite.  This suggests that there exists a threshold number of parasites, regardless 
of strain, that determine lethality.  As few as one RH parasite produces a parasite burden 
sufficient to be considered uniformly lethal, while TgPHIL1 parasites produce a total 
parasite burden nearly a log lower in total number of tachyzoites, but still results in death 
of the host.  This suggests that the rapid replication and dissemination of RH is far in 
excess and evolutionarily disadvantageous to the parasite by not allowing sufficient time 
to encyst in the brain and be horizontally transmitted following predation.  Moreover, 
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mutations in PHIL1 may have an evolutionary advantage by allowing the parasite to 
persist for longer in certain hosts by limiting the speed with which the parasite replicates. 
 The speed of parasite replication likely directly influences parasite virulence in 
terms of parasite load.  Another structural protein, AMA1, is a microneme protein that 
seems to be involved in parasite motility and invasion and the studies described here 
suggest that the more quickly the parasite can disseminate and form cysts, the more likely 
the parasite will have success 64-66.  AMA1 has potential as a malaria vaccine candidate 
given its proposed roles in Plasmodium dissemination 67-69, therefore a tetracyline-
inducible deletion of a conditional AMA1 mutant was utilized and demonstrated that 
parasites depleted of AMA1 are impaired in their ability to attach to host cells and to 
regulate rhoptry secretion in vitro. It was hypothesized that this in vitro defect would 
translate into growth and dissemination effects in vivo thus mice were infected with 
AMA1 parasites and mice were given anhydrous tetracycline to delete AMA1.  These 
parasites exhibited significantly lower parasite burdens associated with very minimal 
cytokine production.  
 Since AMA1-depleted parasites are significantly impaired in rhoptry secretion, 
these data support a model in which AMA1 is required for intimate attachment of the 
parasite with the host cell leading to rhoptry discharge.   There is also evidence provided 
in Chapter III and elsewhere 307, 308, that parasites intimately attach and inject proteins 
into multiple cells before invasion.  This could exacerbate the AMA1 defect in motility as 
the parasite, already defective in attachment, must interact not with one cell but many 
cells before successfully invading a host cell and replicating. Thus, these parasites have 
severely impaired invasion capabilities allowing for rapid clearance by the immune 
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system.  While untreated parasites replicate, although more slowly than RH, and elicit 
strong pro-inflammatory responses, ATC-treated parasites are rapidly cleared from the 
host suggesting that they either do not infect cells at all, may not inject their immune-
modulating rhoptry proteins efficiently, and are more susceptible to anti-microbial 
effector mechanisms. 
 These studies of two structural proteins demonstrate the necessity of the parasites to 
rapidly invade a cell to avoid immune recognition.  The removal of PHIL1 has prominent 
effects on parasite replication and dissemination although these effects do not induce 
acute resistance by the host. RH rapidly kills mice preventing its own horizontal 
transmission, although this robust lethality is unlikely to occur in all species infected in 
nature.  However, mutations in PHIL1 could induce attenuated virulence and greater 
persistence under certain circumstances.  Conversely, AMA1 is required for invasion and 
its removal leads to rapid recognition and destruction of the parasite before the host can 
even mount a robust immune response.  These studies highlight the importance of rapidly 
invading host cells to avoid host resistance and how the speed and efficiency of these 
early invasion events can predict parasite load and mortality. 
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Chapter V. 
 
Conclusions and future directions 
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 Many groups have focused on trying to better understand the basis for innate 
recognition of T. gondii and how this parasite is able to manipulate host-signaling events 
to promote its survival and replication.  Some of the studies presented in this thesis have 
addressed the influence of parasite factors that are involved in motility, invasion, and 
dissemination or the ability of the host to recognize this pathogen.  However, the main 
finding of these studies relates to how IL-6-STAT3-SOCS3 signals impacts immune 
evasion and parasite survival.  These studies highlight the pleiotropic nature of IL-6 and 
specifically how the cytokine is a potent inhibitor of the early production of IL-12 by 
macrophages and neutrophils that is necessary to control the parasite.  This work has also 
built upon much of the recent literature on the interaction of T. gondii with STAT3 and 
incorporated the growing understanding of how SOCS proteins regulate cytokine activity.  
They advance our fundamental knowledge of STAT3 signaling events, SOCS3 and IL-6 
biology, and the roles that these proteins play in determining the outcome of host-
pathogen interactions.  
 
T. gondii hijacks STAT3 signaling 
In 2005, Butcher et al. demonstrated that STAT3 was required by T. gondii to 
inhibit pro-inflammatory cytokine release from activated macrophages 88. This was the 
first observation that a pathogen could directly induce the phosphorylation of STAT3 to 
promote its own survival. This activation of STAT3 was also shown to be independent of 
IL-6 and IL-10 and required for parasite-induced inhibition of IL-12 and TNF-α.  This 
finding was intriguing as both IL-6 and IL-10 have prominent roles during toxoplasmosis 
yet were dispensable for this phenomenon 303.  These observations led to the suggestion 
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that T. gondii might directly phosphorylate STAT3 and a subsequent study by Saeij et. 
al., reported that a parasite rhoptry protein, ROP16, was necessary for STAT3 activation 
although the authors suggested that ROP16 did not act directly to phosphorylate STAT3 
87.  However, subsequent studies revealed that ROP16 has kinase function and can use 
STAT3 as a substrate 308, 342.  Seeking to understand the molecular mechanisms behind 
virulence, another report suggested a link between parasite virulence and the efficiency 
with which the certain strains activated STAT3 87.  Thus, less virulent type II strains had 
a form of the ROP16 protein that did not activate STAT3 as efficiently as virulent type I 
strains.  Further support of a link to virulence was provided by data that suggested that 
the pathogenicity of Type II strains could be enhanced by addition of the type I ROP16 
gene that was associated with impairment of IL-12 production 87, 272.  However, several 
paradoxes remain.  For example, the least virulent Type III strains express a version of 
ROP16 that is efficient at inducing the phosphorylation of STAT3. These contradictions 
and the studies discussed below on the STAT3 conditional-knockout mice suggest that 
differences in parasite virulence are likely more complex than simply the strength of 
STAT3 phosphorylation. 
 
The inhibitory actions of STAT3 
 These studies outline the need to better understand the mechanism by which 
STAT3 moderates pro-inflammatory responses. IL-6 and IL-10 utilize STAT3 to induce 
the anti-inflammatory response (AIR) but exactly how STAT3 mediates inhibition of 
inflammation is unclear and has been a long-standing question in the field. Many other 
stimuli, in addition to the studies on T. gondii described herein, also employ STAT3-
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signaling machinery to reduce inflammation and impair microbicidal function and several 
proposed actions of STAT3 are described in Figure 27. Differences in STAT3 
transcriptional profiles elicited by activators of the AIR may determine why certain 
inhibitors of inflammation like IL-6 and IL-10 do not have identical function.  IL-10 has 
been shown to have strong inhibitory effects on the release of many pro-inflammatory 
molecules from monocytes/macrophages such as TNF-α, IL-1b, IL-6, IL-8, IL-12, G-
CSF, and GM-CSF 343, 344.  IL-10 also induces the release of anti-inflammatory mediators 
such as the IL-1 receptor antagonist and soluble TNF-α receptors 345, 346. Furthermore, IL-
10 inhibits antigen presentation of monocytes and reduces surface MHC Class II and 
CD86 expression 347, 348.  In contrast, IL-6 is typically regarded as pro-inflammatory and 
the inhibitory functions of IL-6 are less well characterized. From this study, IL-6 appears 
to target the production of IL-12 and TNF-α while having no effect on NO production. 
Similarly to IL-10, T. gondii inhibits many activation markers, presumably acting through 
STAT3, such as NO, IL-12, IL-6, TNF-α, and MHC Class I and II 268, 349.  Additionally, 
T. gondii has been shown to interfere with the function of IRGs but it has not been 
investigated if IL-6 and IL-10 are equally capable of interfering with IRG expression or 
loading onto the parasitophorous vacuole 293, 350. There is evidence that Type I strains of 
T. gondii are better at inhibiting IRG colocalization than others but it is not known if this 
correlates with the strength of STAT3 phosphorylation 293.  IL-10 and IL-6 have also 
been implicated in interfering with the microbial killing functions of macrophages 296, 304, 
351, 352, however, the mechanisms underlying these activities are poorly understood and 
have never been contrasted. Additionally, the autophagy-associated protein atg5 is linked 
to parasite killing, IRG loading onto the parasitophorous vacuole, and autophagic  
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Figure 27.  T. gondii interferes with host-cell signaling to limit immune cell 
activation and production of IL-12.  1) IL-6 and T. gondii phosphorylate STAT3 
through the gp130 subunit or its secreted ROP16 protein respectively.  Phosphorylated 
STAT3 then travels to the nucleus.  2) T. gondii blocks phosphorylation of IFN-γ-
activated STAT1 or TLR-activated NF-κB (3) preventing their nuclear translocation and 
upregulation of target genes.  4) Phosphorylated nuclear STAT3, often in conjunction 
with NF-κB, upregulate STAT3-target genes that inhibit the production of pro-
inflammatory genes such as IL-12 (5), induced by phosphorylated NF-κB and STAT1.  
6) SOCS3 is upregulated by STAT3 but does not inhibit IL-12 production.  Instead, it 
acts as a negative regulator of IL-6 signaling to limit the cytokine’s ability to impair pro-
inflammatory cytokine production. 
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clearance that all are likely parts of the same mechanism.  Moreover, there is a 
conditional atg5 knockout with acute susceptibility to T. gondii 169 and it would be 
intriguing to understand whether IL-6 or IL-10 affect this pathway. 
In addition to T. gondii, other pathogens such as Epstein-Barr Virus (EBV), 
Hepatitis C Virus (HCV), and Respiratory Syncitial Virus (RSV) activate STAT3 353 354, 
355.   Convergence on this pathway by these different organisms suggests that STAT3 
signaling is an important mediator of microbial success.  However, as has been described 
above, the consequence of STAT3 signals are context-dependent.  For instance, the 
phosphorylation of STAT3 by EBV in B cells may have entirely difference consequences 
than the activation by T. gondii in macropahges.  In vitro, T. gondii phosphorylates 
STAT3 to limit IL-12 production from macrophages yet this ability was not shown to 
have in vivo implications. Perhaps the phosphorylation of STAT3 is strongly cell type-
dependent; STAT3 signals in macrophages reduce pro-inflammatory cytokine production 
while STAT3 phosphorylation in B cells prevents lytic viral replication and promotes 
latency 356.  Many of the studies on the AIR have focused on the type of STAT3 signal 
provided whether it is from IL-6, IL-10, or IFN-γ and less have described the differences 
in STAT3 signaling by cell type 313, 357.  Thus, it may be relevant to understand that the 
type of cell may be just as important for the generation of a specific AIR as the cytokine 
or microbial stimulus providing it. 
 
Macrophages do not require STAT3 for resistance to T. gondii 
Given the literature that implicated STAT3 as a critical factor for parasite 
virulence that inhibits the production of pro-inflammatory cytokines, it was hypothesized 
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that the removal of STAT3 from macrophages would enhance cytokine production, 
especially IL-12, leading to more effective control of T. gondii or perhaps the 
development of immune potency.  This was not observed.  LysM-cre Stat3fl/fl mice did not 
show enhanced resistance to more the virulent RH parasites, as these mice succumbed to 
infection similarly to wild type mice. LysM-cre Stat3fl/fl mice also showed comparable 
levels of IL-12 with similar survival and parasite burdens when acutely infected with Pru.  
Although these mice did have lower parasite burdens chronically, this did not appear to 
impact survival. These data suggest that STAT3 in macrophages is not a critical mediator 
of to T. gondii. 
It is possible that the lack of phenotype in LysM-cre Stat3fl/fl mice is because 
macrophages and neutrophils are not the relevant cell type for T. gondii-induced STAT3 
phosphorylation.  Perhaps STAT3 is necessary in another cell type such as the dendritic 
cell as they have been shown in other studies to be a significant source of IL-12 during 
toxoplasmosis 106, 358-360.  There are other data, though, that suggest that neutrophils and 
macrophages are important cellular sources of IL-12 so a comparison of these LysM-cre 
Stat3fl/fl mice with CD11c-cre Stat3fl/fl mice may better elucidate the contributions of 
these cells to IL-12 production in vivo 361, 362.   Additionally, although T. gondii can 
activate STAT3 to limit pro-inflammatory responses in macrophages in vitro, the parasite 
may not have the same effect in vivo. Potentially, cre-expressing parasites described in 
Chapter III could be useful.  For example, these parasites could be used to determine if, 
following deletion of STAT3 or SOCS3 in vivo, IL-12 production was affected in certain 
cell populations. These experiments could help define which populations are critical for 
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IL-12 production and whether T. gondii can modify IL-12 signals in macrophages, 
neutrophils, or DCs specifically, in the absence of STAT3 or SOCS3. 
 
Differential effects of STAT3 and SOCS3 in macrophages 
 STAT3 is an important transcription factor that regulates many aspects of the AIR 
and it has been proposed to be a critical mediator of virulence in T. gondii 86, 87, 270.  It was 
then hypothesized that certain proteins upregulated by the AIR downstream of STAT3 
would be required for the ability of T. gondii to inhibit pro-inflammatory cytokine 
production from macrophages.  The first protein that was evaluated for these effects was 
SOCS3 as it is aregulator of cytokine function, is downstream of STAT3 signaling, and 
was upregulated following T. gondii infection 270. While LysM-cre Stat3fl/fl mice had 
largely normal responses to T. gondii, LysM-cre Socs3fl/fl mice were highly susceptible.  
The initial hypothesis was that STAT3 would promote T. gondii survival by upregulating 
SOCS3 to limit pro-inflammatory responses.  Thus, it was surprising that whereas 
STAT3 had no effect on macrophages in vivo, SOCS3 was required in macrophages to 
inhibit the anti-inflammatory properties of IL-6.  Specifically, SOCS3 prevented IL-6 
from limiting IL-12 acutely, an effect which was thought to be STAT3-mediated but 
which was never tested in our studies.  The phenotypes of LysM-cre Stat3fl/fl and LysM-
cre Socs3fl/fl mice are compared in Table 2.  These data highlight the paradox that SOCS3 
expression is considered to be STAT3-dependent yet LysM-cre Stat3fl/fl mice have no 
phenotype while LysM-cre Socs3fl/fl mice have enhanced susceptibility.  This suggests 
that STAT3 is not required in macrophages for parasite control while SOCS3 is necessary 
to limit IL-6 signals.  Increasing this complexity, the inhibitory functions of IL-6 are 
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Genotype Strain Result Notes 
LysM-cre 
Stat3fl/fl mice 
RH Mortality, D7 High, uncontrolled parasite burdens, i.p. 103 
tachyzoites 
Pru Resistance Normal immune response, advances into chronic phase. 
Survival past 50 days, i.p. 104 tachyzoites 
ME49 Resistance Normal immune response, advances into chronic phase. 
Survival past 50 days.  Oral gavage 20 cysts 
LysM-cre 
Socs3fl/fl mice 
RH Mortality, D7 High, uncontrolled parasite burdens, i.p. 103 
tachyzoites 
Pru Mortality,  
D8-10 
High uncontrolled parasite burdens, impaired IL-12 
responses, hyper IL-6 responsiveness, 104 tachyzoites 
   
 
 
Table 2.  Summary of T. gondii infections in LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl 
mice.  This table summarizes how LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl mice respond 
to infection with various strains of T. gondii.  The genotype and strain of T. gondii used 
are listed in the first two columns followed by the effect this had on acute mortality.  
“Resistance” is defined as the infection proceeding into the chronic phase.  Mice were 
sacrificed after 50 days in these cases.  Notes are annotations of the systemic response of 
the infection as well as the type of parasite and route of infection.   
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considered to be STAT3-dependent thus it is unclear why excessive STAT3 signaling in 
the macrophage is detrimental while the absence of STAT3 has no effect.  One potential 
explanation is that although both STAT1 and ERK signaling appeared normal in the 
absence of SOCS3, these molecules have compensatory functions that mask the absence 
of STAT3 in macrophages and are required for these effects in vivo. Another suggestion 
is that in vivo,  IL-6 does not need STAT3 to limit inflammation in macrophages as long 
as it can suppress IL-12 in other cell types, i.e. DCs.  DCs are a prominent cell type for 
IL-12 production, therefore CD11c-cre Socs3fl/fl mice should exhibit a similar phenotype 
to LysM-cre Socs3fl/fl mice as the initial burst of IL-12 is important, regardless of cell type 
106, 363-365.  If CD11c-cre Socs3fl/fl mice are resistant to T. gondii, it would suggest that 
macrophages and/or neutrophils play a more important role in early IL-12 production and 
this is an ongoing debate in the scientific community.  It would also be interesting to 
know if IL-6 can antagonize IL-12 production from DCs or if these effects are cell-
specific and more importantly to determine if the quality or type of AIR induced by T. 
gondii, IL-10, and IL-6 is dependent upon cell type and these effects could be contrasted 
by taking a genomic microarray approach to measure broad transcriptional regulation 
 
Functions of SOCS3 in the immune system 
Presently, there is limited understanding of SOCS3 biology as it relates to 
immunity to infection and many of the proposed functions are highlighted in Figure 28. 
IL-6 has been shown to signal through the gp130 receptor and these events can be 
inhibited by SOCS3 binding to gp130 and inhibiting access of STATs and JAKs to the 
docking site on the receptor 252. SOCS3 is not constitutively expressed but associates with  
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Figure 28.  Proposed intracellular functions of SOCS3. 1) STAT3 is phosphorylated 
directly by T. gondii through the secreted kinase ROP16.  2) Phosphorylated STAT3 
enters the nucleus and upregulates STAT3-dependent genes, some of which are involved 
in turning off IL-12 production.  3) SOCS3 acts to turn off gp130 signaling by binding to 
Y757 on the gp130 subunit.  This is thought to sterically inhibit STAT3 docking to the 
receptor.  4) Additionally, SOCS3 impairs ROP16-mediated phosphorylation of STAT3 
although this mechanism is unclear.  Possible inhibitory functions for SOCS3 are the 
direct binding and inhibition of STAT3 or its upstream kinases or polyubiquitination and 
proteasomal degradation of STAT3 (5), ROP16, gp130, or any other proteins involved in 
this cascade. 
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surface-bound receptors following its upregulation by various stimuli such as IL-6 and 
IFN-γ 252. Its SOCS box, a C-terminal domain with strong homology among SOCS 
proteins, is capable of recruiting E3 ubiquitin ligases domain and binds to elongin BC 
and cullin5, yet direct substrates have yet to be identified 366.  The presence of the SOCS 
box suggests that SOCS3 regulates cytokines through ubiquitination and proteasomal 
degradation of various intermediate proteins such as JAKs, Tyk2, STATs themselves, or 
other related substrates and kinases although there is currently little experimental 
evidence to support this conclusion 257, 258, 367-369.   
It has previously been appreciated that SOCS3 is a negative regulator of IL-6 and 
other cytokines such as IL-27, LIF, and IL-11 that signal through the gp130 receptor, 
however no prominent role for this protein during infection had been described 254, 267, 305, 
370, 371.  Nevertheless, SOCS3 is upregulated in cells infected with a variety of pathogens 
including Leishmania, Mycobacterium, and T. gondii 372, 373.  Although SOCS3 function 
has not been well characterized during infection in vivo, a vital role for the protein during 
development has been identified as SOCS3 deletions in mice lead to impaired 
erythropoiesis and embryonic lethality 374.  Therefore, it was difficult to utilize SOCS3-
knockout mice so a conditional deletion of SOCS3 in macrophage and neutrophil 
lineages, LysM-cre Socs3fl/fl was used for infections. 
 LysM-cre Socs3fl/fl mice succumb to infection with T. gondii by 10 days post 
infection associated with defects in IL-12 production that are mediated by IL-6 signaling.   
Traditionally, IL-6 has been regarded as pro-inflammatory in many experimental settings 
and IL-6-deficient animals succumb to infection with T. gondii during the chronic phase 
of infection associated with a defect in humoral immunity and enhanced parasite burdens 
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(Silver et al., unpublished material) 179. While the data described here do not address how 
SOCS3 specifically inhibits IL-6 signaling, studies using a gp130 hypermorph, mice with 
a mutation in gp130 that prevents SOCS3 binding, are helpful.  In these mice, the failure 
of SOCS3 to bind gp130 results in exaggerated STAT3 signaling and these mice 
succumb to T. gondii infection with impaired IL-12 production similar to LysM-cre 
Socs3fl/fl mice 375.  Combined, these studies demonstrate the requirement for innate cell 
expression of SOCS3 to limit the potentially damaging inhibitory functions of IL-6. 
Somewhat surprising, treatment of chronically-infected mice with neutralizing antibodies 
to IL-6 results in enhanced microbicidal killing associated with decreased inflammation 
and reduced parasite burdens suggesting that IL-6 promotes chronic parasite growth 180.  
IL-10, which also signals primarily through STAT3, is required during the acute phase of 
infection, with IL-10-knockout mice succumbing to infection within the first two weeks 
due to an unchecked inflammatory response and severe immune-mediated pathology 376.  
This effect is not observed in IL-6-deficient mice despite the strong inhibitory effects 
presumably because of the presence of strong IL-10 responses and that fact that IL-6 does 
have anti-parasitic functions that are required for chronic immunity (Silver, unpublished 
data) 180. 
One unexpected result, described in Chapter 3, was that T. gondii induced 
stronger phosphorylation of STAT3 in SOCS3-deficient macrophages.  SOCS3 is 
considered to inhibit only gp130-mediated STAT3 signals, i.e. it does not inhibit IL-10-
induced pSTAT3.  Since ROP16 has not been described to interact with gp130, it is 
surprising that the absence of SOCS3 would affect ROP16-mediated phosphorylation of 
STAT3. The question of why T. gondii induces stronger phosphorylation of STAT3 in 
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the absence of SOCS3 is an interesting one.  Some suggested mechanisms are shown in 
Figure 28.  Given the E3 ubiquitin ligase-recruiting properties of SOCS3, it is possible 
that SOCS3 induces degradation of ROP16, STAT3, or another protein that interacts with 
these proteins. SOCS3 may also recruit phosphatases, such as SH2-domain-containing 
protein-tyrosine phosphatase (SHP)-1, that diminish overall STAT3 phosphorylation and 
additional studies will be required to determine if any of these proposed functions are 
relevant during T. gondii infection. 
 
Final Comments 
Together, the studies presented here outline a fundamental model of host-
pathogen interactions and how one evolves strategies to limit the functions of the other.  
T. gondii, and pathogens in general, have evolved a number of mechanisms to undermine 
host-cell signaling to promote pathogen replication, survival, dissemination, and 
transmission.  This thesis has discussed how T. gondii uses STAT3 to diminish 
macrophage production of pro-inflammatory cytokines and how the macrophage 
upregulates SOCS3 to limit excessive STAT3 signaling.  This thesis has also described 
how inflammatory responses need to be tightly regulated to avoid excessive inflammation 
and how these anti-inflammatory responses can be usurped by pathogens to enhance their 
own success.  Some of the more interesting data to come from these studies was the 
comparison between mice with STAT3- and SOCS3-deficient macrophages.  Initially 
thought to be intimately associated with each other, the dramatic difference in phenotype 
between LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl mice is puzzling.   This suggests a 
complexity in STAT3 and SOCS3 signaling that was previously unappreciated and may 
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depend on cell type and timing of these signals.  It is also curious to know if either 
STAT3 or SOCS3 have different functions in T cells or DCs and whether comparisons 
with targeted deletions of these proteins in those populations can help us better 
understand how cytokines such as IL-6 and IL-10 function in vivo during T. gondii 
infection. 
This thesis began by evaluating whether different strains of T. gondii have unique 
effects on host-signaling.  Despite prior literature to the contrary, the data described in 
this thesis suggest that T. gondii-induced STAT3 may not be different between strains 
and that the differences observed in virulence are more complex with multiple inducers 
of STAT3 having variable effects in different cell types.  These studies highlight the 
utility of targeting SOCS3 and STAT3 for use in therapeutic settings to limit 
inflammation and also support the use of blocking IL-6 for treatment of certain infections 
such as T. gondii and L. major.  There are a number of possible ways to specifically 
target these genes but these effects will be different depending on the context of the 
inflammation or pathogen. Inhibition of STAT3 signals could be achieved by small-
molecule inhibitors of activation, but these efforts would need to be targeted to certain 
cells types creating difficulties.  Potential therapies for decreasing STAT3 signals could 
be the amelioration of pathogen-induced disease or for enhanced production of IL-12 in 
settings where this cytokine is lacking.   The same could be said for SOCS3 where the 
ability to specifically impair IL-6 activity could be somehow inflammation in arthritis, or 
IL-6-mediated inhibition of IL-12 for certain intracellular pathogens such as T. gondii.  
IL-6 is often found upregulated in hyper-inflammatory and autoimmune diseases such as 
multiple sclerosis, arthritis, and Crohn’s Disease.  While blocking IL-6 with the 
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neutralizing antibody tocilizumab has the potential to be used in any condition with 
enhanced IL-6, targeting SOCS3 specifically may have similar effects with less adverse 
effects.  Targeting SOCS3 or using tocilizumab during acute infections or recurring 
infections such as chronic TE in HIV/AIDS patients may also limit sequelae and control 
parasite burdens although side effects such as respiratory tract infections, headaches, 
hypertension (high blood pressure), and liver injury have been reported 377, 378.  As 
STAT3 is activated in a variety of inflammatory, developmental, and infectious 
situations, the utility of affecting the phosphorylation or expression of STAT3 must be 
carefully weighed to specifically target desired pathways and prevent unwanted 
consequences. 
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Appendix 
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During the course of these experiments, many different avenues of research were 
broached but not carried out in any full detail.  Some of these are included here such that 
there may be record should future researchers endeavor to follow up on them.  
The following are experiments very similar to those outlined in this dissertation.  
They are all LPS inhibition assays and the methods for each are discussed in the Methods 
sections in both Chapters II and III.  Briefly, BMMφ were infected with RH or Pru or 
given STAg for 1 hr followed by LPS stimulation for 24 hrs.  ELISAs were performed on 
supernatants.  Bone-marrow was taken from various knockout mice, generously donated 
to the lab from various places over the years.  Many are commercially available.  
Cryopyrin, NALP12, IPAF, and ASC are all proteins involved in the inflammasome 
complex and are reviewed in detail in 379.  It was hypothesized that some of these 
molecules might be involved in innate recognition of T. gondii and/or might be 
responsible for the parasite’s ability to restrict pro-inflammatory responses from activated 
macrophages. Reports from this lab and others demonstrate cRel’s importance in IL-12 
production 99.  Many of these panels are incomplete or negative and their inclusion in this 
dissertation is to provide suggestions for future research. 
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Appendix A-D. Nalp12 and Cryopyrin are dispensable for RH-mediated inhibition 
of LPS-induced cytokine production.  IL-12p40, nitrite, IL-6, and IL-10 were measured 
from macrophages pre-incubated with RH or STAg before LPS stimulation. Nalp12- and 
Cyropyrin-deficient macrophages show the same phenotype for IL-12p40 and nitrite 
inhibition by RH.  IL-6 results are varied.  Curiously, Nalp12-deficient macrophages 
show significantly greater IL-12p40 and IL-10 production than wild type macrophages 
suggesting that Nalp12 is an inhibitor of IL-12 and IL-10. 
 
Appendix E,F. Ipaf- and ASC-deficient macrophages are similar to wild type 
macrophages in cytokine production and play no role in T. gondii-mediate inhibition 
of pro-inflammatory responses. TNF-α and nitrite were measured from macrophages 
pre-incubated with RH or Pru or given STAg before LPS stimulation.  Results are 
indicative of experiments described in this dissertation and Ipaf- and ASC-knockout 
macrophages resemble wild type macrophages for both pro-inflammatory molecules. 
 
Appendix G.  cRel-deficient macrophages produce lower concentrations of IL-12p40 
following LPS stimulation.  IL-12p40 was measured from wild type and cRel-deficient 
macrophages pre-incubated with RH or Pru or given STAg before LPS stimulation.  
Overall IL-12p40 production was significantly lower in cRel-/- macrophages than control 
macrophages as expected.  RH was still able to reduce further the IL-12p40 that cRel-/- 
macrophages could produce suggesting that this protein is not required for this 
phenomenon. 
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